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Abstract 
Glioblastoma is an aggressive, invasive and resistant brain cancer. Despite the promisor 
role of EGFR, targeted therapies failed without giving insights about predictive factors. 
EGFR endocytosis and trafficking have been reported to influenciate therapy resistance. 
Integrin is known as a regulator of EGFR oncogenic activity during tumor progression by 
affecting its trafficking. Previous results from the team in cell evasion showed that α5 
integrin depletion sensitizes cells to gefitinib treatment. For that, my main objective was 
to determine if the endocytic pathway is involved in the integrin-mediated resistance to 
gefitinib. 
Endocytosis involvement on gefitinib treatment was evaluated by dynamin inhibition. 
Dynamin is GTPase involved in the fission of endocytic vesicles. There were performed 
cellular evasion and EGFR internalization assays under gefitinib treatment with or 
without dynamin chemical inhibitiors (dynasore and dyngo4a). We showed that 
endocytosis is involved in the gefitinib-mediated inhibition of U87 cell evasion regardless 
the α5 integrin expression level. Gefitinib induces ligand-bound EGFR internalization, 
being this impaired with the addiction of dynasore. EGFR and α5β1 integrin distribution 
were evaluated using immunofluorescence confocal microscopy. Gefitinib was shown to 
induce internalization of both receptors, being them founded co-localized inside of early 
endosomal vesicles. Gefitinib induced EGFR internalization occurs in U87 and others 
glioma cell lines independently of α5 level. 
We postulate that α5β1 integrin may impact on EGFR trafficking and function during 
membrane trafficking after endocytosis confering resistance towards gefitinib treatment. 
There was already described a regulatory role of integrin in EGFR trafficking to promote 
carcinoma cell invasion, for that this role of integrin should be further evaluated. 
In conclusion, endocytosis plays a relevant role in gefitinib treatment. EGFR trafficking 
gains here a strong evidence for its role in therapy resistance. Modulators of this 
endosomal trafficking, such as α5β1 integrin can predict responsiviness towards EGFR 
targeted therapies. 
Keywords: Glioblastoma, EGFR, Gefitinib, α5β1 Integrin, Endocytosis  
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Graphical abstract: Dynamin inhibition enhances gefitinib resistance. Gefitinib 
treatment induces EGFR internalization independently of integrin expression level. α5 
integrin depletion sensitizes cells to gefitinib treatment, since there is no evasion under 
these conditions. When endocytosis is impaired, cells become resistant (with a more 
evading behaviour) to gefitinib independently of α5 level. α5β1 integrin may impact on 
EGFR trafficking and function during membrane trafficking after endocytosis confering 
resistance towards gefitinib treatment. 
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Resumo 
Glioblastoma é um dos tumores cerebrais mais agressivos, sendo extremamente invasivo 
e resistente à terapia. Na sua progressão ocorrem diversas alterações génicas, sendo uma 
delas a amplificação e/ou mutação do gene erbB 1.  
O gene erbB 1 codifica o receptor tirosina cinase EGFR, um receptor de sinalização que 
está envolvido em muitos processos celulares Incluindo a migração, constituindo um 
importante alvo terapêutico no tratamento do glioblastoma. No entanto, as terapias 
dirigidas não têm  sido bem sucedidas em ensaios clínicos. De momento, não existem 
quaisquer marcadores predictivos que determinem o carácter responsivo de um paciente 
a este tipo de terapia. Em outros tipos de cancro, já se encontram descritos diversos 
mecanismos de resistência, sendo um deles a cooperação entre EGFR e outros receptores, 
como por exemplo com as integrinas. 
As integrinas são receptores de adesão celular. Em particular, a integrina α5β1  
desempenha um papel importante na progressão do glioma, sendo um descrito alvo 
terapêutico. Esta integrina encontra-se sobreexpressa em estadios mais avançados da 
progressão do glioma, estando associada a um pior prognóstico e a um carácter mais 
invasivo e resistente do tumor.  As integrinas e receptores de factores de crescimento 
como o EGFR cooperam em diversos níveis. A regulação do trafego intracelular já se 
encontra descrita como um mecanismo de resistência a terapias. 
Devido ao interesse do grupo no papel da integrina α5β1 na progressão tumoral do 
glioblastoma, foi previamente geneticamente manipulada uma das mais comuns linhas 
celulares de glioblastoma (U87). Esta manipulação teve como objectivo a sobre-
expressão e a sub-expressão da integrina α5. Estas linhas celulares foram tratadas com 
gefitinib, um inibidor tirosina cinase especifico para o receptor EGFR, e foi avaliada a 
evasão celular. A evasão celular foi avaliada através da migração de células de um 
pequeno agregado celular (esferoide).  As células com níveis acrescidos de integrina α5 
demonstraram um comportamento resistente após o tratamento com gefitinib. Foi 
também verificada uma internalização do receptor EGFR após tratamento através da 
técnica de imunofluorescência. 
Perante estes resultados os objectivos do meu trabalho foram a verificação do papel da 
endocitose no tratamento com gefitinib e a importância da integrina α5β1 neste fenótipo.  
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A endocitose foi perturbada pela inibição da dinamina.  A dinamina é uma GTPase 
envolvida na remodelação da membrana celular. Em mamiferos, a família das dinaminas 
é composta por três isoformas homólogas mas com diferentes padrões de expressão. A 
dinamina 1 encontra-se apenas expressa em neurónios, a dinamina 2 tem uma expressão 
ubíqua e a dinamina 3 encontra-se expressa no cérebro e nos testículos. A dinamina está 
envolvida na fissão de vesículas endociticas, sendo esta função dependente da sua 
actividade como GTPase. Após a ligação de GTP, a dinamina polimeraliza em torno do 
pescoço da vesícula. A hidrólise do GTP altera a conformação da dinamina, levando a 
fissão da vesícula pela geração de forças. A inibição da dinamina foi provocada por dois 
inibidores químicos diferentes.  Dynasore é um inibidor não competitivo da actividade 
GTPase de ambas dinamina 1 e 2.  Dynasore interfere com a actividade catalítica da 
proteína. Dyngo-4a é um inibidor mais potente, embora seja mais selectivo para dinamina 
1 do que para dinamina 2. Dyngo-4a inibe a atividade GTPase ao ligar-se ao domínio G 
responsável pela ligação e hidrólise ao GTP.   
A evasão celular foi avaliada com o tratamento com gefitinib e com ou sem inibição das 
dinaminas. Observou-se uma diminuição da evasão celular após tratamento com gefitinib, 
verificando-se novamente um carácter mais resistente por parte das células que sobre-
expressam integrina α5. A inibição da dinamina reverte completamente o efeito negativo 
do gefitinib em relação à evasão celular, independentemente do nivel da integrina α5. 
Observou-se ainda um aumento da evasão celular com os inibidores da dinamina mas 
apenas na presença de gefitinib. 
O efeito do gefitinib e dos inibidores da dinamina na internalização do ligando EGF foi 
avaliado recorrendo ao uso de EGF acopolado com fluorforo. Pode verificar-se que o 
tratamento com gefitinib aumenta a internalização do ligando, sendo este aumento inibido 
com a inibição da dinamina. Este fenótipo é integrina α5 independente semelhante ao 
estudo da evasão celular. 
Para se averiguar a importância da endocitose no tratamento com gefitinib, 
imunofluorescência foi efetuada com anticorpos anti-EGFR e anti-EEA1. EEA1 é um 
marcador de endosomo inicial, sendo este a primeira estrutura vesicular após 
endocitose/internalização. Foi demonstrado que, após tratamento com gefitinib, EGFR é 
internalizado e encontra-se em proximidade de EEA1. Esta co-localização aumenta com 
o tempo de incubação com gefitinib e é integrina α5 independente. Isto demonstra a 
importância da endocitose neste tratamento. 
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Para determinar se as integrinas também são internalizadas após tratamento com gefitinib, 
foi realizada imunofluorescência usando anticorpos anti-EGFR e anti-integrina α5 ou 
integrina β1. Foi demonstrado que após tratamento, EGFR é internalizado juntamente 
com as integrinas. Devido à limitada resolução da microscopia confocal, esta co-
localização foi confirmada por microscopia de super resolução, mais propriamente 
microscopia estocástica de reconstrução optica. Deste modo, confirmou-se a proximidade 
destas duas proteínas dentro de estruturas endomembranares. 
Para verificar se este fenómeno de endocitose ocorre transversalmente em diferentes 
linhas celulares de glioma foi realizada imunofluorescência usando anticorpos anti-EGFR 
e anti-integrina β1. Verificou-se que o EGFR foi internalizado em todas as linhas 
celulares, e que este fenótipo é independente do nível de expressão de integrina α5, visto 
que as linhas celulares que apresentam um fenótipo mais marcante são as que quase não 
expressam esta proteína. É de reforçar que nestas linhas celulares apenas foi averiguado 
a occorrência da internalização de EGFR e integrina β1. Para averiguar o carácter 
resistente ou sensitivo destas células ao tratamento com gefitinib é necessário futuramente 
realizar estudos de evasão celular. Além do mais, foram utilizadas as condições de 
tratamento de gefitinib usadas na linha celular U87.  Não foram efetuados nenhuns 
estudos de toxicidade ou efetividades do gefitinib, de modo a determinar as condições 
ótimas de concentração e duração de tratamento. 
Os resultados obtidos sugerem que a migração é independente da endocitose do receptor 
EGFR, visto que quando a endocitose do receptor é impedida a migração celular é 
aumentada. A internalização do receptor EGFR após tratamento com gefitinib aparenta 
ser uma forma de diminuir a sinalização do receptor. A influência da integrina α5 na 
resistência ao tratamento com gefitinib deverá ser independente da endocitose, 
provavelmente tendo um papel  após a internalização do receptor Alguns estudos 
mostraram que as alterações no tráfego dos receptores bem como a promoção da sua 
reciclagem por parte das integrinas funcionam como promotores de tumorigénese e 
potenciam a progressão tumoral. No caso do glioblastoma ainda não se encontram 
descritas alterações no tráfego de receptores como promotores de progressão tumoral.  
Deste modo, este trabalho é um inovador ao demonstrar a importância da endocitose e do 
trafégo intracelular na resistência à terapia em glioblastoma.  
Palavras-chave: Glioblastoma, EGFR, Gefitinib, Integrina α5β1, Endocitose  
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1. Introduction 
1.1 Glioblastoma 
 
Epidemiology  
In Europe, central nervous system (CNS) tumors are the 17th most common cancer type, 
with 57 100 new cases diagnosed in 2102. They are the 11th cause of cancer death, with 
around 45 000 deaths in 2012 (1). Glioblastoma (GBM) is the most common and most 
aggressive malignant tumor in CNS representing 20% of all the primary brain neoplasm. 
GBM are the highest-grade astrocytoma and remained essentially incurable. Despite 
numerous efforts, the overall 5 years survival rate does not exceed 5 years and median 
survival is around 15 month (2). GBM can appear anywhere in the brain, but their 
preferred localization is the supratentorial region, having edema surrounding the tumor 
(3). GBM is more prominent in men than women, having a peak of incidence between 45 
and 70 years old (2).   
Risk factors for CNS tumors 
The risks factor associated with GBM development are ionizing radiation, decreased 
susceptibility to allergy and immune factors and genetic alterations. There are single 
nucleotide polymorphisms (SNP) that increase risk of GBM with inherited variation, in 
the chromosome 9p21 that contain cyclin-dependent kinase inhibitor 2B gene, and two 
SNPs in the regulator of telomere elongation helicase 1 (3,4). 
Symptoms of GBM  
The usual symptoms englobe headache, seizures, nausea, vomiting and hemiparesis.  The 
diagnosis is made by cranial magnetic resonance imaging (fig.1.1) (3,4). 
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Figure 1.1: Magnetic resonance image from a glioblastoma tumor. 
Adapted from (5) 
 
Glioblastoma classifications and characterization 
For decades, brain tumor classification was based on their histology and the microscopic 
similarities observed on light microscope after various coloration. This bring to the 
creation of groups of tumors that can be highly heterogeneous such as the astrocytoma or 
the oligodendrocytoma. In 2016, the World Health Organization (WHO) presented a new 
classification of CNS tumors based in integrated phenotypic and genotypic parameters 
(Fig.1.2) (6). Glioblastomas are now classified as grade IV diffuse astrocytic and 
oligodendroglial tumors. Glioblastomas are further segregated depending of their  
analysis of IDH status. IDH-wildtype GBM represent 90% of the GBM and the other 10% 
shared a genetic driver mutation on IDH1 and IDH2 genes. The evaluation of IDH status 
is made by R132H IDH1 immunohistochemistry and IDH sequencing. When IDH 
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evaluation cannot be performed, the GBM are denominated GBM NOS (not otherwise 
specified) (6).  
 
   Figure 1.2:Diffuse astrocytic and oligodendroglial 
 tumours subcategorization in 2016 WHO  
Classification for CNS tumors. Adapted from (6) 
 
But in this classification the subcategorization of GBM is only based in one molecular 
marker, the IDH status.  
GBM can also be divided into de novo and secondary GBM, each characterized by 
different pathways (Fig.1.3). De novo GBM doesn’t have evidences of previous lesions, 
being 80% of all GBM and usually affects older patients (over 55 years old). 
Genetically, de novo GBMs are characterized by HER1 amplification, PTEN mutations 
and p16 deletions. They are also IDH1 wild type and mutated in hTERT promoter. The 
chromosomal events underneath de novo GBM formation could be the amplification of 
12q14 region, where are encoded the CDK4 and MDM2 genes, occurring then a disruption 
of p53 and Rb1 pathways; the homozygous deletion of 9p, where are encoded the genes 
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p16, p15 and p14 ARF; the loss of heterozygosity of 10q, where are encoded the gene 
PTEN. HER1 amplification is found in 40% of de novo GBM, followed by mutations that 
result in the constitutive activation of EGFR. PTEN mutation is found into 45% of de 
novo GBM, leading to a constitutive activation of PI3K/AKT pathway.   
Secondary GBM affects young patients and develops from previously described low 
grade astrocytoma or anaplastic astrocytoma. In secondary GBM there are low grade 
genetic alterations, such as TP53, PDGF-A, Rb1, ATRX, and IDH1. (2,4,7,8).  
 
 
Figure 1.3:Molecular changes in primary brain tumor progression. In orange there is represented 
the cell cycle alterations, in green the signaling pathways alterations and in blue the heterozygous 
alterations. Adapted from (7) 
In a preclinical study, Verhaak et al described four subtypes of GBM (Proneural, Neural, 
Classical and Mesenchimal) based on gene expression, demonstrating a greater inter 
heterogeneity between patients. In figure 1.4, are represented the main genetic alterations 
that distinguish these subtypes. The proneural subtype is characterized by alterations of 
PDGFRA, points mutations in IDH1 and TP53 mutations. Focal amplification of 
PDGFRA is associated also with high levels of PDGFRA gene expression. Tp53 
mutations were associated with loss of heterozygosity. Its signature also has proneural 
developmental genes (SOX, DCX, DLL3, ASCL1 and TCF4) and oligodendrocytic ones 
(PDGFRA, NKX2-2, OLIG2) (9). The neural subtype has expression of neuron markers 
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such as NEFL, GABRA1, SYT1 and SLC12A5 (9). Classical subtype has the typical 
GBM amplification of chromosome 7 and loss of the 10. Classical GBM are characterized 
by high expression levels of erbB1, without the presence of mutations on TP53. However, 
alterations in RB pathway with homozygous deletion of CDKN2A are found. In this 
subtype there are also expression of neural precursor markers NES, as markers from 
Notch and Sonic Hedgehog pathways (9).  The classical subtype is more responsive to 
therapy (temozolomide/radiotherapy). Finally, the mesenchymal GBM are characterized 
by the focal hemizygous deletion at 17q11.2 leading to loss of NF1. The expression of 
mesenchymal markers (CHI3L1 and MET) is associated with epithelial-to-mesenchymal 
transition. The significant existence of necrosis and inflammation can be explained by the 
expression of genes from TNF and NF-Kb pathways (TRADD, RELB) (9). 
Intra-tumoral heterogeneity is a hallmark of GBM. To explain this heterogeneity there 
are three theories: the clonal evolution, the cancer stem cell theory and interclonal 
cooperativity. In the clonal evolution, the initial cell suffers somatic alterations giving 
arise to different clones that are genetically unstable. From these clones, only the ones 
with the most aggressive behavior and less sensitive to therapy are favored and survive. 
In the cancer stem cell theory, only a group of cells have the ability to self-renew, 
continuous proliferation and ability to give arise to different clones. Numerous works 
describe that these cells are also resistant to therapy. In the interclonal cooperativity 
theory, the heterogeneity is due to the interactions between tumor cells and a changing 
microenvironment (immune cells, stromal cells and the extracellular matrix). For 
example, tumor evolution and self-renewing of glioblastoma cancer stem are affected by 
the hypoxic perivascular niche (9–11). 
Intra-heterogeneity has a relevant clinical implication because it usually leads to therapy 
failure. So it should be important to perform the molecular analysis in distinct tumor 
biopsies from different parts of the tumor (10).  
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Figure 1.4: Gene expression of the four subtypes of glioblastoma. The heatmap represents three 
different sources of DNA, where DNA microarrays for the main genes that characterized each 
GBM subtype were analyzed. The results are represents in a gradient colorated scale when 
green means a loss of expression and red a gain of expression. Adapted from (9). 
 
Glioblastoma Invasive behavior  
GBM is a very locally invasive tumor. This migration capacity allows cells to develop 
tumor in the opposite hemisphere from the primary site or even multifocal GBM tumors 
(3).  
Primary brain tumors have a unique pattern of invasion and rarely metastasize outside of 
the brain. Usually GBM cells, invade as single cells to almost anywhere in the brain. They 
infiltrate along blood vessel walls periphery, corpus callosum of neural fibers and 
astrocytes glia limitans externa.  This invasion phenotype is not the same in tumors that 
metastasize to the brain, since these are more static, and when they invade it happens in 
group and only in short distances (13). 
 
During evasion, cellular morphology changes (fig.1.5). When GBM cells migrate along 
blood vessels, they present a spindled shape with a single pseudopodium that extends 
toward the movement direction by polarization of actin polymerization. When they 
migrate through the brain parenchyma, they present multiple pseudopodia pointed in 
different directions. One of these directions will be chosen and be an invasion guide. 
GBM cells migrate using mesenchymal motility form that is dependent on the adhesion 
to the extra cellular matrix (ECM) and their remodulation. The invasion results then on 
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the combination of cell shape, position and tissue architecture, being needed PI3K 
signaling activation and also small GTPases. The pseudopodium interacts with ECM 
mainly through integrins and their focal adhesion complexes, acid hyaluronan receptor 
CD44. These two receptors have as main ligands proteins that are abundant in brain 
parenchyma as hyaluronan, collagen, fibronectin and laminin. ECM is remodeled by 
serine proteases, cysteine proteases and metalloproteases (MMP). In the serine proteases, 
the most studied is the complex urokinase-type plasminogen activator (uPA)/ uPA 
receptor that activates plasmin and degrades fibronectin and laminin. In the cysteine 
proteases, Cathepsin B is involved in laminin and collagen degradation and in GBM 
invasion. In GBM, the most important MMPs involved in cell invasion are MMP-2 and -
9. The inhibition of these MMPs leads to less migration and invasion in glioma cell lines 
and also in glioma cells xenografts. Tissue inhibitors of MMP (TIMP) modulates the 
proteases activity by forming complexes with them. Their addiction is reported to 
decrease cell invasion (14–18). 
 
Invasion is a process with multiple involving factors that can be targeted in a way to treat 
GBM.  
 
Figure 1.5: Hypothetic model of GBM progression. Two distinct cellular morphologies whether 
cells invade along the periphery of blood vessels (I) or through the brain parenchyma (K). 
Adapted from (19). 
 
Glioblastoma Treatment 
GBM treatment starts with surgical resection, followed by radiotherapy and 
chemotherapy. Until 2005, after surgical resection were performed a radiotherapy with 
adjuvant carmustine, a nitrosourea drug with alkylating function (4). A clinical trial (trial 
22981/26981) showed that concomitant administration of temozolomide (TMZ) with 
radiotherapy, with adjuvant TMZ resulted in a better survival for the patient with minimal 
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levels of toxicity (20). Surgical resection is decompressive and cytoreductor, being associated 
with the increase of survival if there is complete resection of the tumor. To facilitate the tumor 
removal, a tumor fluorescence derived from 5-aminolevulinic acid is used to enhance the contrast 
of normal-tumor tissue (21).  
The radiotherapy used in the study was a fractionated focal type, where occured a 
irradiation of 2 Gy/ fraction, once a day for five days/week, for a period of six weeks 
(total of radiation given to the patient was 60Gy) (22).  
The drugs used to treat GBM must be able to cross the blood-bran barrier (BBB), so they 
must have a low molecular weight, high lipidic solubility and low ionization, and they 
also must have minimal protein binding capability (23). TMZ is an oral alkylating agent. 
It is a pro-drug that is spontaneous converted to the active metabolite, imidazole-4-
carboxamide. It is able to methylate DNA, in N-7 or O-6 positions of guanine residues. 
TMZ is a small, lipophilic compound and so it is able to cross the BBB (24,25). TMZ is 
given concomitantly with radiotherapy for the following reasons: 
- A daily administration of low doses has a greater intensity of activity without 
additional toxicity, 
- After radiotherapy, the enzyme MGMT is activated and repairs the DNA 
damage. A continued administration of an alkylating agent such as TMZ depletes this 
enzyme. 
- It was observed an in vitro synergetic effect by the concomitant use of TMZ and 
radiotherapy. 
- TMZ was also chosen by its capability of crossing the BBB and the spontaneous 
conversion into the active metabolite (MTIC).  
TMZ was administrated daily, all days of the week during radiotherapy, and for 5 days in 
the adjuvant six cycles that occurred during 4 weeks (22).  
Even with treatment, the median survival rate is less than a year, between 9 to 15 months 
(26).  After recurrence, the tumor is often different from the primary. The recurrent tumor 
doesn’t respond well to TMZ, and it also presents high expression levels of VEGF. In a 
clinical trial for recurrent GBM, combined treatment with bevacizumab (humanized IG1 
monoclonal antibody for VEGF) and irinotecan (topoisomerase1 inhibitor) gives a 
survival rate of 7-9 months after treatment, similar to the conventional treatment (27).  
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Predictive and prognostic factors of GBM 
Predictive factors/markers are used to evaluate the responsiveness to a treatment, with the 
objective of stratifying the patients according to the benefit or not from a specific 
treatment. Prognostic factors/markers are used to evaluate the overall outcome of the 
patients (28,29). 
In GBM, there are good prognostic factors such as young age at diagnosis, cerebral 
location and maximal tumor resection. The Methylation status of the O6-methylguanine-
DNA methyltransferase (MGMT) promotor, IDH1/2 mutation, erbB1 amplification, 
glioma-CpG island methylator phenotype (G-CIMP), TP53 mutation and losses of 
chromosomes are genetic prognostic factors. The MGMT is an enzyme that removes alkyl 
groups from the O6-guanine, producing a resistance to alkylating agents. After 
methylation of the MGMT promotor, this one is silenced and cells are incapable to repair 
the DNA damage and become more sensitive to TMZ. MGMT promoter methylation has 
then a prognostic significance. Besides this, MGMT promoter methylation also has a 
predictive one since it predicts tumor responsiveness to alkylating agents such as TMZ. 
The MGMT promoter is methylated in approximately 50% of GBM, being associated 
with IDH1/2 mutations (common in secondary GBM). In IDH1/2 mutations the more 
frequent ones are in IDH1 appearing mainly in secondary GBM. This mutation is 
associated with lesions with less necrosis and small areas of tumor, having then a more 
favorable prognosis. G-CIMP occurs in 10% of GBM, more common in secondary ones, 
being associated with IDH1/2 mutations (3,30). Mutations in ATRX cause alternative 
lengthening of telomeres, being present associated with IDH1/2 and TP53 mutations, 
mainly in secondary GBM. TERT mutation is most frequent in de novo GBM, being 
correlated with erbB1 amplification and a shorter patient survival (3,30). EGFR 
overexpression was associated with worse prognosis in younger patients bearing Tp53-
wildtype tumors, while in older ones appears to have a better prognosis. So, TP53 
mutations are not a definitive prognostic marker (3,30).  
Cancer initiating tumor cells 
Tumor initiating cells (TIC) are a subpopulation of cells in a tumor. These cells have 
some stem cell properties such as: renewing capability, unspecialized characteristics and 
capability to become into differentiated cells. To evaluate these stem cells properties, 
must be study the self-renewal properties and their capability to initiate a tumor (31,32). 
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Neural stem and progenitor cell are cell types present in the brain, expressing both 
CD133+. In Singhs et al study, CD133+ cells with stem cell properties in vitro were 
isolated from human brain tumors. CD133+ GBM cells represent a proportion between 
3-30% of the tumor. These cells were capable to produce tumors in NOCID mice. These 
tumors resemble the human tumor in the expression of markers such as nestin, MIB-1, 
GFAP, MAP2. In the tumor obtained, were found CD133 positive and negative cells, and 
the CD133+ cells were different to MAP2+ cells. These data evidence that the CD133+ 
initiating cells could give arise to differentiated cells. These study showed that the 
hypothesis of TIC in GBM should be taken seriously, due to the fact that conventional 
therapies don’t kill them, having them the possibility to allow tumor progression or 
relapse (33). Sub-populations of TIC have high levels of SOX2, OCT4, and NANOG, all 
known to maintain self-renewal and cellular proliferation (30).  
Effect of brain tumor in BBB permeability 
Brain tumors increase BBB permeability by disruption of tight junctions (TJ) and due to 
increased angiogenesis. It is well known that GBM is characterized by a high level of 
angiogenesis. In GBM, vessels are tortuous and leaky. One growth factor responsible for 
angiogenesis, VEGF, is present in high levels in GBM. VEGF enhances endocytosis of 
VE-cadherin, and consequently there is a disruption of the endothelial barrier, increasing 
in this way also its permeability. Other factors produced in GBM, such as TGF-β2, 
caveolin-1, ROS and aquaporins, induce secretion and activation of MMPs that degrade 
TJ. It has been reported the loss of claudin3 and occludin in primary brain tumors that 
enhances disruption of BBB permeability. In GBM there are also increased levels of 
membrane transporters such as folate and insulin receptors that can facilitate the entry of 
molecules through the BBB. By another way, even with BBB permeability changed, 
others mechanism involved into the protection of chemical entry into the brain are intact. 
It has been shown that the expression of P-gp was not altered in GBM, remaining 
functional and limiting the brain diffusion of chemicals such as therapeutic drugs .  
Pre-clinical models of glioblastoma  
GBM cell culture is a useful tool to study cell processes before using tumor behavior in 
animal models. Usually, a cell culture has optimized conditions for proliferation and 
survival of the cells. The medium used supply the cells with all metabolites, growth 
factors and cytokines. But tumor cells in culture have unlimited oxygen and optimal pH, 
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and that is not the reality in vivo due a hypoxic microenvironment. Furthermore, in culture 
the cells don’t have a three-dimensional interaction with the other cells and matrix. To 
overcome this, there are spheroids models that mimetic it (37). 
Due to selection pressure on cell culture, genetic alterations can occur and alter the genetic 
and phenotypic profile of the cancer cell lines in comparison to the original tumor (38). 
After a study between solid primary GBMs and GBM cell lines were identified 160 
proteins gained and 60 proteins lost in culture, losing then the GBM heterogeneity and 
making difficult any comparation between in vitro and in vivo. One of this lost is EGFR 
overexpression (27–31). 
The GBM cell lines are obtained from human brain diagnosed with GBM, astrocytoma 
grade IV. After the excision of the tumor, some cells are put into petri dishes. Here most 
of the cells die, and the ones which survived after a few passages become into an 
immortalized cell line. For glial cells, Pontén and Macintyre in 1968 were the first ones 
to optimize the culture conditions (39).  
One of the usual GBM cell lines is U87. Genetically, U87 is hypodiploid human cell line, 
that easily forms tumors when injected in mice. These tumors have a huge vessels network 
(40).  
The use of tumor initiating cell lines that are maintained in serum free conditions with 
growth factors (PDGF, bFGF, EGF) and growth as tumor spheroids are able to retain the 
tumor phenotype and tumor initiating capacity. But it was shown that growth of tumor 
initiating cells in adherent culture maintains highly pure stem cells populations (41,42).  
Patient derived xenografts (PDX) are a tool to improve pre-clinical studies, since the 
tumor cells grow in an in vivo environment. PDX can be made using fresh tumor samples 
or cryopreserved ones (tissue cryopreserved at low temperature right after tumor 
excision). The single cell suspension can be implemented in the brain (orthotropic) or in 
the mice flank (heterotopic). But that was reported that heterotopic PDX do not 
demonstrate a local invasive profile compared to the orthotropic ones. This different can 
be explained by the different microenvironment in the two cases. But even in orthotropic 
xenograft, the murine brain microenvironment is different molecular and functionally 
from the human. The xenograft should be done in mice lacking immune system, since it 
was demonstrated that residual active immune system prevents tumor formation (43,44). 
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As we can see, GBM is a malignant and higly resistant tumor. Its biology needs to be 
better studied. One interesting therapeutic target in GBM is EGFR, since it is founded 
overexpressed in 40% of the cases. EGFR is a signaling receptor that is involved in the 
main signaling pathways that leads to cell migration and invasion, which are typical in 
GBM. 
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1.2 EGFR 
 
EGFR and Glioblastoma 
The discovery of EGFR in malignant transformation was made in the 80’s by oncogenic 
viruses that showed EGFR as a cellular homolog of the avian erythroblastosis virus v-
erbB oncogene (45). 
The EGFR signaling network is critical for tumor progression because it promotes cancer 
cell survival, growth and invasion. In GBM, erbB1 the gene encoding of the EGFR/ErbB1 
protein is amplified is 40-60% after gene rearrangement and/or focal amplification. This 
amplification is often associated with mutations. These mutations can lead to ligand 
independent activity of the receptor, and are also reported to enhance motility and 
invasion by inducing genes of the extracellular matrix, metalloproteases and serine 
proteases. erbB1 mutations in GBM are common, and they can be N-terminal truncation 
(EGFRvI), deletion of exons 14 – 15 (EGFRvII), deletion of exons 25 – 27 (EGFRvIV), 
C-terminal truncation (EGFRvV) and C-terminal duplications and truncations. The most 
common mutation in GBM is EGFRvIII (occured in more than 50% of the GBM cases). 
EGFRvIII is a truncated protein due to loss of exons 2-7, that gives arise to a 801 base 
pair deletion. The amino acids 6-273 are replaced by a glycine residue, and so the resulted 
protein is a 145 kDa glycoprotein with constitutive, ligand-independent activation. The 
constitutive activation is due the reduced interaction with E3-ligase Cbl, leading to a 
reduced degradation of the receptor which a negative feedback regulation system. 
EGFRVIII is also occurs in lung, breast, ovarian and prostate cancers (37–39,41,42).  
As described above, EGFR overexpression has a relevant role in GBM progression.   
EGFR is a signaling receptor that is involved in diverse cellular processes, like cell 
migration and invasion (characteristics of GBM). 
 
HER family 
EGFR belongs to a family called HER family, which has four transmembrane receptors: 
EGFR (HER1), ERBB2 (HER2), ERBB3 (HER3) and ERBB4 (HER4) (50). 
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The EGFR is a 170 kDa glycoprotein, with 1186 amino acids that is composed by three 
main domains: an extracellular ligand-binding domain (ectodomain), a hydrophobic 
transmembrane domain and a cytoplasmic tyrosine kinase domain (46,47,50).  
Figure 1.6: Schematic of ErbB receptor structure and its dimerization and activation. A – 
Schematic of ErbB receptor showing the different parts: ectodomain (L1,L2 – leucine-rich 
domains, CR1, CR2 – cysteine rich domains), transmembrane domain, tyrosine kinase domain 
and c-terminal tail. B- Schematic of dimerization and receptor activation: i- receptor in inactive 
state, ii- ligand binds to L1 and L2 changing receptor conformation, iii- receptor dimerize 
through cysteine domains, creating docking sites in tyrosine kinase domain, iv- ErB2 in is 
inactive state has the same conformation that the rest active receptors. Adapted from (47).  
The ectodomain contains four subdomains: two leucine-rich subdomains (in figure 1.6 
L1 and L2) and two cysteine-rich subdomains (in figure 1.6 CR1 and CR2). The leucine 
domains directly bind to ligand, while the cysteine domains are involved in interaction 
and dimerization with others receptor. The leucine domain is different between the family 
members, giving to them different ligand specificity.  
While, the cytoplasmic domain is a highly conserved bilobed tyrosine kinase. Only HER3 
does not have kinase activity. Between the two lobes there is a ATP binding site. The 
activation of the receptor by ligand binding (between L1 and L2) creates an extended 
conformation.  This expose the dimerization loop present in CR1, allowing dimerization. 
In this moment, occurs the interaction between the N-lobe of one domain with the C-one 
of another, creating phosphorylated binding sites as docking sites (46,47,50). 
The EGFR known ligands are EGF, TGFA/TGF-𝛼, amphiregulin, epigen/EPGN, 
BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Some of them 
are cell membrane anchored proteins that are proteolytically disrupted to become soluble 
molecules that will induce EGFR activation. Their cleavage by metalloproteinases can be 
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activated by GPCR. The ligands can be overexpressed by active Ras or steroid hormones 
(47,50). EGFR can also be activated by ligand-independent mechanism. Ligand-
independent activation can be induced by unphysiological stimuli (such as oxidative 
stress, UV, and irradiation), by others RTK (such as MET, IGFR) or by GPCR and 
adhesion receptors like integrins (51). In GBM, MET is also found dysregulated, being 
this a possible cause for anti-EGFR therapy resistance. EGFRvIII is described to be a 
activator of Met, and so the dual treatment is shown to reduce tumor growth (52,53).  
EGFR activation is attenuated by tyrosine dephosphorylation of active receptor, by  
phosphatases such as density-enhanced phosphatase-1 and PTP1B. Their catalytic 
activities eliminate the sites in which signaling intermediates or adaptor proteins would 
bind and promote cell signaling (47). However little is known about the involvement of 
PTP1B in glioma progression and invasion. 
EGFR signaling pathway  
Receptor homo- and/or heterodimerization occurs after ligand binding, followed by 
activation of the tyrosine kinase activity with consequent tyrosine autophosphorylation 
on the cytoplasmic specific residues (Fig.1.6) (47,50).  
These phosphorylated residues become docking sites for adaptor proteins such as Grb2 
(binds to pY1068 and pY1086) or Shc (binds to binds pY1148 and pY1173), that can 
activate RAS/Raf/MAPK downstream signaling cascade (45,47).  MAPK pathway is 
activated through the interaction between the Grb2 and SoS, leading to proliferation, 
migration, angiogenesis and differentiation. p38-MAPK in GBM is linked to invasion and 
angiogenic phenotypes (54,55).  Its inhibition leads to decreased tumor growth in glioma 
xenografts (56). MAPK pathway is also involved in regulation of neural stemness (57). 
EGFR activation leads to the stimulation of the PI3K/Akt pathway through the 
recruitment of the regulatory subunit p85. Whereas EGFR and ErbB2 receptors bind 
indirectly to p85 through adaptor proteins like Gab1, ErbB3 and ErbB4 directly bind to 
p85 (47,51). PI3K pathway is often dysregulated in GBM, since their negative regulators 
are frequently mutated, for example the loss of PTEN is founded in 45% of GBM cases. 
Studies targeting signaling pathways of this cascade such as mTOR are showing 
regression in GBM (58,59).  In GBM, p85 can be also activated by direct interaction with 
cancer stem cell marker CD133, leading to PI3K activation (60).  
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All ligands and receptors of the family can activate the signaling cascade like 
Ras/Raf/MEK/MAPK, PI3K, PLC- γ and STAT. These signaling pathways are involved 
in glioma progression (fig.1.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The EGFR TK domain has numerous substrate proteins like STAT family members. 
STAT3 binding to activated EGFR leads to STAT3 dimerization and translocation into 
the nucleus (46,47,51). In GBM, the co-expression of EGFR and the mutant EGFRvIII 
activates STAT3/5 leading to glioma progression. EGFR phosphorylates the mutant 
receptor, allowing its nuclear entry where it forms a complex with STAT3. This study 
shows that EGFR not only function as a signaling receptor but also as a transcription 
factor (61). EGFR has a tyrosine residue (Tyr 992) that allows direct interaction with 
PLC-γ leading to actin reorganization and asymmetric motile phenotype (45,46). In 
GBM, was reported that the activation of  PLC-γ and STAT3 leads to migration and 
invasion (62).  
 
 
Figure 1.7: Schematic of some EGFR signaling pathways involved in 
glioma progression. After EGFR activation and auto phosphorylation are 
created docking sites for signaling molecules. EGFR interacts with Grb2 
mediator to activate MAPK pathway. PI3K pathway is activated on the 
plasma membrane and the signal is controlled by PTEN. PTEN is usually 
mutated in GBM. EGFR can also activate directly STAT3 and PLC-γ 
pathways 
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Endocytic pathway of EGFR 
Internalization of the EGFR has contradictory results. Endocytosis of EGFR constitutes 
a regulatory mechanism of this signaling pathway, having different described functions. 
The internalization can attenuate the signal leads to receptor degradation, or also allows 
the continuation of the signal by endosomal signaling and/or recycling of the receptor 
back to the plasma membrane. Indeed, EGFR membrane trafficking is required for 
activation of specific transducers and has been shown to play critical role in cancer cell 
invasion, as described below. Two main steps compose the endocytic pathway: the 
internalization of the receptor and its trafficking in intracellular compartments (Fig.1.8)  
(63,64). 
The internalization controls the levels of receptors that are present at the plasma 
membrane, regulating their accessibility to ligands.  
There are described diverse endocytic pathways that lead to EGFR internalization, being 
the most important the clathrin-dependent pathway. Clathrin-independent pathway was 
described to be used in high levels of EGF environment. Also the internalization pathway 
can be chosen by the type of ligand bound to the receptor: EGF and TGFα induces 
clathrin-dependent pathway, while HB-EGF a clathrin-independent pathway. Inactive 
EGFR is usually associated with caveolae rafts. After ligand binding, EGFR moves out 
from there, dimerize and enter into the cell by clathrin-dependent endocytosis. The 
binding of Grb2 to EGFR allows its ubiquitination by E3 ubiquitin ligase Cbl on pY1045. 
Once ubiquinated, EGFR interacts with Eps15, allowing the binding to the clathrin-pit 
through AP-2 (65,66). The ubiquination of EGFR promotes its lysosomal degradation. 
There are also negative feedbacks produced after EGFR activation that lead to signal 
attenuation, such as the production of suppressor of cytokine signaling-5 (binds to EGFR 
and promotes its degradation), Sprouty-2 (modulates Ras/MAPK pathway), LRIG-1 
(promotes Cbl binding and EGFR ubiquitination) and Mig6/RALT (binds to TK domain 
αI helix of EGFR, inhibiting its catalytic activity) (45,47,66). Sprouty-2 is a novel 
therapeutic marker in GBM, being usually expressed in commitment with EGFRvIII (67). 
Mig6 is a tumor suppressor that was described to regulate EGFR trafficking and suppress 
glioma progression (68).   
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After receptor endocytosis, this enters in a system of intracellular vesicles called 
endosomes. The first ones are the early endosomes where occurs the sorting of the 
receptor:  unbounded receptor recycled quickly back to the plasma membrane, while 
ligand-bound receptor recycled slowly or are degraded in lysosomes (Fig.1.8) (64,69).  
Ligand dissociation can influenciate the fate of the receptor. The endosomal pH 
influenciates ligand dissociation since EGF remains bound to the receptor while TGFα 
dissociates. Because of that EGF leads to EGFR degradation and TGFα to EGFR 
recycling (70). 
Ubiquitinated EGFR is sorted in the early endosomes by ESCRT machinery to 
intraluminal vesicles of maturating endosomes. From here the receptor is taken to 
lysosomal degradation (45,65). 
Recycling of the receptor can occurs by the short loop (controlled mainly by Rab4) or by 
the long loop (controlled by Rab 11) (65). 
Dysregulation in receptor trafficking has been described as a tumorigenesis promotor. 
Defects that leads to poor downregulation are associated with enhanced signaling. One 
described mechanism is the sustained PI3K signaling due the loss of SPRY2 that leads to 
EGFR/HER2 internalization and early endosomal signaling in a PTEN-dependent 
manner. This leads to proliferation and invasion in prostatic cancer (71). The interaction 
between EGFR and HER2 also overcomes ubiquitinated signaling attenuation, leading o 
recycling of the receptor (45,46). Increased EGFR recycling was described a mechanism 
that drives hepatocellular carcinoma metastasis (72).  
Trafficking dysregulation involved in GBM progression has not been described so often. 
There was described a overexpression of NHE9 (Na(+)/H(+) exchanger) and its 
involvement in stemness, therapy resistance and invasion in GBM. NHE9 limits the 
luminal acidification of endosomes, promoting EGFR recycling and consequently 
signaling continuation (73).   
EGFR endosomal signaling has also been reported. It was described AKT signaling in 
early endosomes through the APPL1, a Rab 5 effector. Rab 5 is the main characteristic 
protein of early endosomes. And also p38 MAPK sustain early endosomes signaling by 
promoting clathrin-mediated EGFR endocytosis and degradation evasion (65).  
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Therapies against EGFR 
Since EGFR is involved in tumor progression, it becomes a promise target for therapy in 
hope to eradicate the tumor. There are different approaches used in target therapy against 
EGFR: the use of antibodies that block ligand binding or the use of small molecules that 
inhibit tyrosine kinase activity of the receptor (47,50). 
Antibodies 
The antibodies used against EGFR bind to the extracellular domain, induce the 
internalization of the receptor to try to inhibited the signaling pathway, but also is a 
potential stimulator of the immunological response. One of the most known is cetuximab, 
a chimeric antibody with high specificity for EGFR. Cetuximab is an EGF antagonist, 
and so it competes for the natural ligand-binding sites, preventing ligand binding and 
receptor activation. It was approved by FDA on February 2004 for colorectal cancer 
treatment. Panitumumab is a fully humanized antibody against EGFR, approved by FDA 
on September 2006 for treatment of colorectal cancer with KRAS wildtype. Both 
antibodies are given by intravenous injection (47,50). 
Tyrosine kinase inhibitors 
The small molecules called tyrosine kinase inhibitors (TKI) are synthetic molecules with 
low molecular weight, almost all are quinazoline-derived and they bind to intracellular 
domain of the receptor through a hydrogen bond (fig.1.9). TKI are homologous to 
adenosine triphosphate (ATP), competing for the ATP-binding domain of kinases 
(fig.1.10).  In this way, TKI prevent the EGFR autophosphorylation, the activation of 
tyrosine kinase and the signaling pathway.  
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One of the most known TKI is gefitinib that reversibly inhibits the TK activity of isolated 
EGFR with an IC50 in the nanomolar range. But in vivo, higher concentrations are required 
to block EGFR due the presence of intracellular ATP. It should be considered that in 
higher concentrations, gefitinib not also inhibit EGFR but also others RTK such as erbB2. 
Gefitinib has a half-life of about 28 hours. For that in clinic, gefitinib is administered 
daily, in a dose around 600mg/day. Gefitinib is metabolized by cytochrome P450 3A4 
(CYP3A), being the inter-variability of this enzyme (expression and activity) one of the 
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reasons for different susceptibility to treatment. Gefitinib upregulates p27 (cell cycle 
inhibitor) and downregulates c-fos (transcription factor) and so gefitinib leads to a cell 
cycle arrest in G1 phase. In clinic, gefitinib is being used for treatment of locally advanced 
and metastatic non-small cell lung cancer (NSCLC) harboring EGFR-activating 
mutations (47,50,74–80). 
Others TKI are also being used in clinic: erlotinib, an EGFR inhibitor, is being used in 
metastatic NSCLC and pancreatic cancer; lapatinib, an EGFR/erbB2 inhibitor, is being 
used in advanced or metastatic breast cancer. (81,82).  
 
 
 
 
 
 
 
 
 
 
 
 
 
     Figure 1.9: TKI mechanism of inhibition. a  - Schematic  of 
activated RTK bounded to ATP, b -  inhibition by TKI (KI) that 
competes for ATP binding site and forms a hydrogen bond with 
the receptor. Adapted from (83). 
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Secondary effect of EGFR therapies  
Both ways of EGFR targeted therapy cause skin rash and diarrhea, due to direct biological 
effect of EGFR inhibition. So they are considered predictive factors of response to 
therapy.  They have also a warning for pulmonary toxicity, in which cases 1% is fatal. 
And it should be controlled also the hepatic toxicity due to increase of liver transminases, 
normally asymptomatic (50). 
Resistance to EGFR-targeted therapies 
Despite the development of various therapeutic strategies and new compounds, the results 
of anti-EGFR targeted therapies remain somehow discouraging. Most of the tumors are 
resistance to therapies or relapse after a short period. In solid tumors, there is well 
documented mechanism of resistance to EGFR-targeted therapies. Some of these 
mechanisms are the acquisition of secondary EGFR point mutations and alterations or 
ATP 
Figure 1.10: Structure of ATP and Gefitinib. ATP has 
adenine ring that is encircled and it is responsible for 
forming hydrogen bonds with the ATP-binding site on 
RTK. Gefitinib has a quinazoline group, where is founded 
the atom (indicated with red arrow) that form hydrogen-
bonds with the kinase residues. Adapted from (79,80). 
Integrin alpha5beta1 and resistance to cancer therapies 
 
23 
 
redundancy in the signaling pathways.  In NSCLC, the mutation T790M in exon 20 and 
the amplification of MET, another tyrosine kinase receptors are predictive biomarkers for 
a non-responsive profile of the patients to EGFR-targeted therapies. In colon carcinoma, 
the activating KRAS mutation leads to resistance and only patient bearing KRAS-wild type 
tumor are eligible to the cetuximab treatment (47,50,75).  
Glioblastoma are refractory to EGFR targeted therapy and the resistance mechanisms are 
still not understood, and there is no predictive marker (49,81,83,84). Even if preclinical 
studies using anti-EGFR therapies in GBM were promising, the reality in clinical trials 
was very different, with no beneficial results compared with others therapies. Related to 
TKI, phase I/II of erlotinib as a single agent demonstrated promising disease control and 
response rate, while for gefitinib it seems to have clinical activity but no improvement in 
survival. The ability of TKI to enhance radiation sensivity observed in vitro, were not 
demonstrated in any clinical study.  Related to EGFR antibodies, clinical trials using 
cetuximab or nimotuzumab in monotherapy or with other treatments showed a small or 
none activity and response rate (table 1.1). Another antibody (mAb 806) that targets the 
normal and the mutated receptor have promising pre-clinical results and seems having 
tolerance in phase I trials (81,85,86). Some of probable causes for resistance in GBM are 
compensatory activation with other ErbB family, tumor initiating cells, tumor 
heterogeneity, the BBB and the structure of the new vessels. 
 
 
 
 
 
 
 
 
 
Table 1.1: Clinical trials using TKI in glioma. Adapted from (87). 
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The BBB is a greater barrier against anti-cancer agents that were administrated 
systemically. The compounds to penetrate BBB should present higher lipophilicity.  The 
tortuous vasculature also limits the drug penetration into the brain (83,87). The amount 
of gefitinib found in the brain is different among several studies. In NSCLC patients with 
brain metastasis, the ratio of gefitinib between cerebrospinal fluid and plasma was only 
0.3-1.3% (88). This is in agreement with the prediction of low capacity to penetrate BBB 
since gefitinib is highly water-soluble. Also gefitinib is a substrate of the p-glycoprotein 
efflux pump that is expressed in brain tumors. But in some studies, there were observed 
penetration of gefitinib into the brain (89,90). This can be explained by the altered BBB 
integrity and the low level of CYP3A in brain (81,91) . 
The tumor initiating cells (TIC) tend to be resistant to therapy by altering the checkpoint 
and DNA repair pathways.  These cells are being associated with the presence of multiple 
drug resistant transporters. The existence of this transporters lead to the efflux of drugs, 
reducing their concentration in the brain (83). The activation of others receptors of the 
ErbB family were demonstrated as a mechanism of resistance for EGFR-targeted therapy 
in glioblastoma TIC (84). 
Intra tumor heterogeneity is normally one of the most common reasons for therapy 
resistance. The heterogeneity can lead to redundancy and cross talk between signaling 
pathways. Besides EGFR overexpression, can also occur the mutation and amplification 
of others RTK and GPI-linked receptors (IGFR1, MET, PDGFR α/β, uPAR) which 
signaling compensates the EGFR inhibition. It has also been proposed that deletion of the 
tumor suppressor gene PTEN, leading to the continuous activation of PI3K pathway, 
prevent inhibition of EGFR signaling pathway by TKIs (81,83). In retrospective analysis 
association of EGFRvIII and wild-type PTEN was reported as a significant predictor of 
TKI response in GBM. But this predictive value was not observed in others studies 
(49,92,93).  
Dysregulation of receptor trafficking can be stress-induced or a way to overcome cell 
death as described above. This dysregulation promotes tumor progression and can be also 
a mechanism of therapy resistance. But still few is known about that and so require further 
investigation (65,94,95). 
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As we can see there are molecular markers that predict the insensitivity of lung and colon 
tumors to EGFR targeted therapies. But in GBM there are not yet such biomarkers that 
can explain the failed clinical trials using first generation of EGFR TKI such as erlotinib 
and gefitinib (93).  
The causes for resistance to EGFR therapies in GBM are unknown, but preclinical data 
in other cancer types correlate the crosstalk and bi-directional regulation of EGFR and 
integrins as one possible mechanism of therapy resistance (85,96–98). 
1.3 Integrins 
 
Integrins Family 
Integrins are a family of heterodimeric cell surface receptors composed by non-covalent 
association of alpha and beta subunits. The family is composed by 18 α subunits (that 
determine ligand binding specificity) and 8 β subunits (that connects to cytoskeleton and 
signaling molecules), forming 24 different receptors that each binds to one or more ECM 
ligands (fig.1.11).  
There are four families based on the evolutionary history of α subunits. The first group is 
composed by integrins that recognize the arginine-glycine-aspartic acid (RGD) motif on 
their ECM ligands such as fibronectin, vitronectin or fibrinogen. The second group is 
formed by laminin binding integrins. In this group, there is the special β4 that has a large 
intracellular domain and so function as a docking site due to its phosphorylation sites. 
The last two groups (leukocyte integrins (β2) and collagen integrins (β1) receptors) come 
from the same large group of integrins that are structurally different from the others 
groups due to an extra domain in their α subunit (96,99).   
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Figure 1.11: Family of integrins.Adapted from (93) 
 
Integrin expression and function 
Integrins are expressed in all cell types, however the profile of integrin vary from cell 
type to cell type. Integrins and their ligands are important in the early stages of embryonic 
development including in fertilization, implantation and in blastula formation. β1 integrin 
is one of the most important, since its homozygous knockout leads to early death of the 
embryo. It can be due to the fact that β1 is present in 12 of 24 combinations of integrins 
(99,100). 
In the physiological development, maintenance and remodeling of tissues, stem cells have 
an important role. Stemness is regulated by signals from the stem cell niche 
microenvironment such as the ECM. In here, integrins have an important role, mainly β1 
that is highly expressed in stem cells to maintain stemness and control the balance 
between renewal and differentiation. In this context, the role of integrins in cell fate is to 
give spatial cues to the cells, due to the interaction with ECM and their mechanosensor 
activity, while the temporal cues are given by growth factors (100,101). 
Integrins regulate cellular processes such as survival, proliferation, differentiation, 
migration, adhesion, apoptosis, anoikis, polarity and in stemness (96–99). 
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Integrins signaling pathways 
After ligand binding, the integrins as a surface receptors undergo a conformational change 
from inactive state to an active one that have a higher avidity for ligands. The inactive 
state is characterized by a bent conformation with a closed head piece, while the active 
one has an extended conformation and an open head-piece, so then the conformational 
change occurs in the extracellular β-subunit followed by the separation of the intracellular 
domains of both subunits (99,101–103).  
Integrins have a mechanical and biochemical role. 
The recognition of different ligands allows these receptors to sensitize different 
environments, forming so a physical connection between the inside and the outside of the 
cell. Integrins are relevant in attachment of cells to ECM but also in cell-cell interactions. 
This mechanical function of integrins is related mostly with their capacity of connecting 
with actin cytoskeleton through the formation of complexes with talin, paxilin, α-actinin, 
tensin and vinculin. The promotion and generation of contractile forces contributes to 
migration of cells (99,100). 
Because integrins do not have enzymatic activity, they need to recruit cytoplasmic kinases 
to perform their signaling function. Integrins transmit signal through focal adhesion 
kinase (FAK), integrin linked kinase (ILK), talin, paxilin, Src, PI3K and Ras/MAPK. 
These interactions are mediated by the β subunit of integrin. This subunit has NPX/Y 
motif that allows the physical interaction with PTB domains. After ligand binding, FAK 
is recruited by the β subunit, and then it autophosphorylates (Tyr397), creating a docking 
site for Src. This active complex FAK/Src activates a lot of downstream pathways such 
as NF-kB, MAPK and PI3K. This recruitment of signaling molecules also potentiate the 
activity of tyrosine kinase receptors such as VEGF, FGFR and EGFR. ILK binds to β 
cytoplasmic tail and upregulates the activity of AKT. (99,101,104).  
Integrins and Cancer 
With playing so many roles in cell biology, mainly on proliferation, survival and 
migration, integrin defective signaling can result in a number of pathologies such as 
cancer (100). 
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In most cases integrins are overexpressed in cancer tissue compared to normal one (table 
1.2). In some solid tumors, the epithelial cells that give arise to the tumor as the same 
integrins expression as the normal cells, normal and cancer cells express α2β1, α3β1, 
α6β1, α6β4. Integrin expression can be different between normal and tumors cells, like 
integrins αvβ3, α5β1 and αvβ6 which are almost undetectable on epithelia but their 
expression are upregulated in carcinomas, such as colon, breast, ovarian, lung and gastric 
(98,100,105). 
 
Since expression and signalinf of integrins are cell-type dependent, there is not a 
consensual role of integrin overexpression in cancer as an anti- or pro- tumoral. Some 
integrins are also downregulated in tumors, such as α2β1 in breast cancer and α3β1 in 
melanoma (106,107). 
Integrins expression in both tumor and stromal cells has an important role in metastasis. 
This expression promotes cell motility and anchorage-independent growth through 
activation of FAK/PAK/MAPK by integrin β1. Integrins were also associated with 
Table 1.2: Integrin overexpression in cancers. α5β1 is 
overexpressed in various types of cancer. In 
glioblastoma are present the overexpression of α5β1, 
αvβ3 and αvβ5. In the table there are also represented 
integrin-targeted drugs. Volociximab is used against 
α5β1, etaracizumab against αvβ3, cilengitide and 
intetumumab against integrin αv, and  ATN-161 against 
α5β1 and αvβ3. Adapted from (97,105). 
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metalloproteases and UPA, enhancing their activity. The interaction of integrins and 
GFR, described below, also promotes invasion through the enhancement of signaling 
pathways. Integrins signaling also influenciates cancer stemness, drug resistance and 
metastasis (101).The cancer stemness has a role in the initiation of tumor but also in 
resistance to therapy. (97,101,108). The altered expression of integrins in 
microenvironmental cells, such as endothelial cells, promotes angiogenesis, desmoplasia 
and immune responses (97,98,101,105). Integrins exert their oncogenic activity throught 
the crosstalk with tyrosine kinase receptor such as EGFR, MET or PDGFR. Integrin/grow 
factor receptor (GFR) cooperation can also lead to therapy resistance (97,101,108). 
Studies of expression and function of integrins in glioma revealed an important role of 
these receptors in progression and survival of patients. Overexpression of ECM 
component like fibronectin (ligand of α5β1 and αvβ3) is associated with gliomagenesis 
and poor survival (109). Integrins αvβ3, αvβ5 and α5β1 were found highly expressed in 
human glioma explants (110).  Integrin αvβ3 was demonstrated as a negative prognostic 
factor in GBM (111). Our laboratory demonstrated that α5β1 integrin  is a diagnostic, 
prognostic and therapeutic factor in GBM. α5β1 integrin was found overexpressed in 
glioma grade IV compared with the low grades and normal tissue. This overexpression 
was associated with a more aggressive phenotype, in which patients had less survival rate 
when α5 was overexpressed. Also the expression of this integrin was associated with 
resistance to one of traditional treatment (TMZ). Moreover, our laboratory and others 
demonstrated the role of α5β1 integrin in glioma cell migration and dissemination 
(108,113–116). 
All data mentioned above, show that integrins are potential therapeutic targets in GBM. 
Currently, in clinical trials there is a cyclic peptide inhibitor of both integrins αvβ3/αvβ5, 
Cilengitide. Cilengitide seem to be well tolerated and to have a small anti-tumor efficacy 
(118). Unfortunately, a clinical trial phase III in GBM with combination of cilengitide 
with chemoradiotherapy did not show any increase of the overall survival of the patients 
(119). 
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Integrins and Growth Factor Receptors 
Integrins and their ligands were demonstrated to collaborate with growth factor receptors 
(GFR). This collaboration is involved in aggressiveness of solid tumors. 
Their interaction can be classified as concomitant or collaborative signaling, direct 
activation and amplification of signaling. The difference between concomitant and 
collaborative is that in the first they act independently, while in the second integrin are 
necessary to assist the proper GFR signaling. In direct activation, integrins activate GFR 
even without the presence of growth factors. While in the amplification of signaling, GFR 
increases the levels of integrins that per se can activate/promote GFR signaling (fig.1.12) 
(96).  
  
Figure 1.12: Mechanisms of interaction between integrins and growth factor receptors. Adapted 
from (96) 
Integrins can positively regulate RTK signaling by directly phosphorylating them. This 
phosphorylation usually occurs in the same tyrosine residues, that are phosphorylated 
after EGF stimulation (120). 
Integrins are not only positive regulators of RTK signaling. It was reported that the 
interaction between α1β1 and collagen, recruits T cell protein tyrosine phosphatase 
(TCPTP). TCPTP dephosphorylates EGFR, PDGFR and VEGFR, leading to signaling 
attenuation (121). 
The interaction between EGFR and α5β1 integrin has been reported in in vitro and in vivo 
models of diverse cancers.  
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In epidermoid cancer, the inhibition of α5β1 integrin, reduces phosphorylation of EGFR 
(residues 1086 and 1148), leading to attenuation of PI3K and MAPK signaling pathways. 
The inhibition of both EGFR and α5β1 integrin suppresses the phosphorylation of 
downstream molecules that are involved in tumor proliferation (122).  
In breast cancer the interaction between EGFR and β1 integrin is important to migration 
and invasion of cells, through the complex Src/EGFR/β1 integrin in the plasma membrane 
that recruits MMP and maturates invadopodia (123).  
In Bronchial cancer, the regulation of EGFR signaling by β1 integrin is necessary to tumor 
migration (124).  
Integrins/EGFR interaction can lead to resistance to EGFR-targeted therapies (table 1.3).  
In breast cancer, a survival mechanism to lapatinib is β1 integrin dependent. Being this 
integrin also associated with low response rate to trastuzumab (125,126). 
In lung cancer model, α5β1 integrin was associated with resistance to cetuximab. β1 
integrin was found in erlotinib resistant lung cancer stem cells and associated with 
resistance to gefitinib treatment (124,127,128).  
 
Integrins trafficking 
Membrane trafficking of integrins has a role in regulation of cell-ECM contacts 
remodeling, being important during regulation of cell adhesion, on cell migration, 
invasion and so is involved in cancer progression. For example, the internalization of 
Table 1.3: Integrins involved in EGFR-targeted therapies resistance. Integrins and their 
ligands are found to be a cause of resistance to anti-EGFR drugs (antibodies and TKI) in 
diverse cancer types. Adapted from (97,101) .  
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integrin α5β1 through caveolin is important for fibronectin turnover, while the clathrin 
pathway has an important role in mitosis (96). The route chosen for integrins endocytosis 
is cell type- and microenvironment dependent. Usually integrins are endocytosed by 
clathrin- or caveolin- dependent pathways. There are also endocytosed by 
micropinocytosis from circular dorsal ruffles or by Rho-A dependent form. The nature of 
the ligands and the interactions with GFR modulate integrin endosomal trafficking 
(96,129,130).  
After endocytosis, integrins undergo endosomal sorting on early endosomes, where their 
fate is decided (recycling or degradation). The movement of integrins to EEA1 positive 
early endosomes is mediated by Rab 21 and Rab5. The recycling of integrin can occur by 
the short/Rab4 loop or by the long/Rab11 loop. This choice depends on different factors: 
the activation state, the crosstalk with others integrins, GFR or downstream molecules. 
Some examples are described below. The inactive state usually recycle by the short loop 
while the active one by the long loop. Integrin αvβ3 suppresses recycling of α5β1 leading 
to migration. Src-mediated phosphorylation of syndecan-4 inhibits Arf6-dependent α5β1 
recycling, stabilizing the focal adhesion and promoting cell migration. There are different 
molecules that promote integrin recycling. Rab 25 interacts with α5β1 integrin that are in 
endosomes to promote their recycling. Rab coupling proteins associate with α5β1 integrin 
and EGFR to promote their recycling after treatment with cilengitide (131). The receptor 
degradation into lysosomes, due to ubiquitin signal in the α chain of integrin, is a slow 
process that leads to a cytoplasmic localization of the receptor. Normally, this occurs to 
the active receptors that still have  the ligand attached (96,105,129,130). 
Trafficking of integrin and EGFR can regulate their signaling and response to therapy, 
being for that an interesting research subjet. 
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1.4 Objective  
The group previously showed that during evasion from 3D stumor spheroids, loss of 
integrin α5 expression in glioblastoma cell line (U87) sensitizes cell to EGFR-targeted 
therapy (gefitinib) (fig. 1.13). The cooperation between EGFR and integrin happen at 
different levels, being one of which in the endocytic pathway.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
My objective was to determine if endocytosis is involved in integrin-dependent resistance 
to gefitinib. 
As written above EGFR is internalized by clathrin-dependent pathway after activation 
(45). In the other hand, integrin are also described to be internalized by clathrin pathway 
(96). Clathrin pathway is dynamin-dependent, our strategy was thus to inhibit dynamin 
mediated endocytosis using chemical inhibitors (132). 
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Figure 1.13: Loss of integrin α5 expression in glioblastoma 
cell line (U87) sensitizes cell to EGFR-targeted therapy 
(gefitinib). Dose effect of gefitinib (concentration in µM) on 
cell dispersion of U87 α5+ and U87 α5-  cells. The number 
of dispersed cells was quantified after DAPI-labelling of 
their nucleus by a ImageJ macro and data were expressed as 
the ratio of dispersing cells compared to control (DMSO-
treated) cells. Turkey-boxes represent data from 3 
independent experiments. Statistical analysis was made 
using ANOVA ***p<0.001. Adapted from (unpublished 
data).  
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2. Methods 
2.1 Cell culture 
The cell lines used are described on table 2.1. The U87 cell line was previously 
manipulated to have an overexpressed or downregulated integrin α5 expression level. 
U87 cells were previously stably transfected with pcDNA3.1 plasmid containing the 
human α5 integrin gene to overexpress the gene. The downregulation of the gene was 
obtained by transfecting the cells with a pSM2 plasmid coding a shRNA against α5 
mRNA.  The transfection was performed using jetPRIME (Polyplus transfection).  The 
cell selection was made using cell sorting with PE-conjugated SAM-1 antibody, and after 
controlled by immunoblotting (108,114). 
The brain tumor cells were cultured in EMEM with L-Glutamine (Lonza, Verviers, 
Belgium), supplemented with 1% sodium pyruvate (Lonza, Verviers, Belgium), 1% non-
essential amino acids (Lonza, Verviers, Belgium), 1% of fetal bovine serum (FBS) 
(Dominique Dutscher, Brumath, France). 
Cells were routinely cultured on 75cm2 flask and maintained on an incubator at 37ºC and 
5% of CO2 under humidified atmosphere. Culture medium was changed every 3 days 
(10ml for a 75cm2 flask). Cells were splited at 80% confluence. The medium was 
aspirated to avoid any serum residues because it inactivates trypsin due to the presence 
of protease inhibitors such α1-antitrypsin and α2-macroglobulin. Two ml of a 
trypsin/EDTA (Lonza, Verviers, Belgium) solution diluted ten-fold in DPBS (Lonza, 
Verviers, Belgium) was added.  Cells flasks were placed at the incubator during five 
minutes. Cells detachment was controlled under the microscope. The trypsination was 
stopped with 2 ml of serum-complemented medium. The cell suspension was placed on 
a falcon tube and centrifugated during five minutes at 1000 rpm (300g).  The cell 
concentration was determined on TC20TM Automated Cell Counter (Bio-Rad, Hercules, 
USA) adding cell suspension and trypan blue dye 0.4% (Bio-Rad, Hercules, USA) at 1:1. 
The supernatant was aspirated and the pellet resuspended in complete culture medium. 
Cells were seeded at 500 000 cells in a 75cm2 flask. 
For long term storage, cells were freezed at -80ºC in cryovials in cell culture medium 
containing 20% serum and 10% of Dimethyl-sulfoxide (DMSO) (Sigma Aldrich, 
St.Louis, USA). DMSO acts as a cryoprotective agent. Cells were thawing by placing the 
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cryovials in a 37ªC water-bath and the cell suspension was transfer to a T-flask 25 cm3 
containing supplemented medium with 10% of FBS. To avoid cellular damage provoked 
by DMSO, the medium was replaced the day after. 
All processes were performed under sterile conditions, under the PSMII Safe Fast Classic 
(Dassit, Ferrara, Italy). 
2.2 Formation of tumoral spheroids 
The formation of spheroids was performed using the hanging drop method, where cells 
are grown in a drop, allowing the formation of a single spheroid (fig.2.1). The method 
used was previously described by Blandin (114). Cell were suspended in culture medium 
containing 10% of methyl cellulose solution (Sigma, St.Louis, USA), at a density of 1,000 
cells/20µl. Cell suspension  was scattered throughout a petri dish in form of 20 µl drops.  
This plate was later inverted and maintained in a humid environment, at 37°C and 5% 
CO2, for 48 hours.   
The spheroids were then seeded on a fibronectin coated surface (fig.2.1) to evaluate the 
evasion of cells. This way for studying evasion resembles an in vivo situation where cells 
migrate from a small cluster. 
24-well plates were coated for 2-3 hours with a 10 µg.ml-1 fibronectin solution (250 µl 
per well). Excess fibronectin was aspirated and wells washed with cell culture medium. 
Each well was seeded with 3-5 spheroids. When indicated dynamin inhibitors (Dynasore 
(Santa Cruz Biotechonology, Dallas, USA) and Dyngo-4a (Selleckchem, 
Souffelweyersheim, France)) or EGFR tyrosine kinase inhibitor (Gefitinib (ChemiTek, 
Indianapolis, USA) were added in the culture medium when spheroids are plated on 
fibronectin coated surface.  
Phase contrast image of the spheroids were obtained with 5x objective using microscope 
EVOS xl Core (Thermo Scientific, Braunschweig, Germany). After 24 hours of 
incubation, cells were fixed in glutaraldehyde 1% (Electron Microscopy Sciences, 
Hatfield, USA) for 30 minutes. Following, wells were washed with PBS and cells were 
stained for 30 minutes with DAPI (2.5 µg.mL-1) (Santa Cruz Biotechonology, Dallas, 
USA). Nucleus were picturized under the objective 5x in the fluorescence microscope 
ZEISS-Axio (ZEISS, Oberkochen, Germany). Image analysis to evaluate the number of 
cells that migrated out of the spheroid was performed with ImageJ software using a 
homemade plugin (Romain Vauchelles, PIQ platform) (114).  
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Table 2.1: Glioma cell lines used. 
Cell line Characterists References Origin 
U87 
Glioblastoma with PTEN mutated (splice deletion 
of exon 3, intron 3 and codon 54), homozygous 
deletions in the p16 and p14ARF genes, TP53 and 
EGFR wild-type. ATCC provided cell line reported 
as different from the original U87 and also Uppsala 
U87MG. 
(39,133–136) 
Obtained from ATCC 
(Molsheim, France) 
 
LN443 
Glioblastoma with PTEN mutated (splice deletion 
exon 5), homozygous deletions in the p16 and 
p14ARF genes and TP53 wild-type. Cross 
contamination with  LN-444. 
(135,137) 
Provided by Professor 
Hegi (Lausanne, 
Switzerland) 
LN229 
Glioblastoma with mutated TP53 (codon 98 
CCT(Pro)→CTT(Lys)), homozygous deletions in 
the p16 and p14ARF genes, EGFR and PTEN wild-
type. 
(135,136) 
 
Provided by Professor 
Hegi (Lausanne, 
Switzerland) 
SF767 
Anaplastic astrocytoma with TP53, PTEN and p16 
and p14ARF genes wild-type, and EGFR 
amplified. 
(135,136,138) 
 
Provided by Dr. Rigot 
(Marseille, France) 
U373 
Glioblastoma with PTEN deleted and TP53 
mutated (codon 273 CGT(Arg) →CAT(His)), and 
EGFR amplified. 
(135–137,139) 
 
 
Obtained from ATCC 
(Molsheim, France) 
 
T98 
Glioblastoma with mutated TP53 (codon 237 
ATG(Met)→ATA(Ile)), homozygous deletions in 
the p16 and p14ARF genes, PTEN deleted and 
EGFR amplified. 
(135–137,140) 
Obtained from EACC 
(Saint Quentin Fallavier, 
France) 
LN319 
Human astrocytoma with mutated  TP53 (codon 
175 CGC(Arg)→CAC(His)) and 
mutated PTEN  (codon 15 AGA (Arg)  → AGT 
(Ile)). Cross contamination witg LN-992. 
(135,137,139) 
 
Provided by Professor 
Hegi (Lausanne, 
Switzerland) 
LNZ308 
Glioblastoma with deleted TP53, and mutated 
PTEN (splice deletion of exon 6), and EGFR wild-
type. 
(135–137,139) 
 
Provided by Professor 
Hegi (Lausanne, 
Switzerland) 
SF763 
Anaplastic astrocytoma with mutated TP53 (codon 
158 CGC (Arg)→CTC(Leu)), homozygous 
deletions in the p16 and p14ARF genes and PTEN 
wild-type. 
 
(135,138) Provided by Dr. Rigot 
(Marseille, France) 
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Figure 2.1: Schematics of spheroid evasion assay. Spheroid formation was performed using the 
hanging-drop method, where methylcellulose prevents non-specific interactions between cells 
and the plastic. After 48 hours, spheroids were plated on a previous fibronectin (FN)- coated 
surface and allow the evasion. DAPI stain was made and quantification of evading cells made by 
a home-made ImageJ plug-in. 
 
2.3 Preparation of Methylcellulose solution 
Six grames of methylcellulose are dissolved in 250 ml of EMEM medium without FBS. 
Then the solution is heated at 60°C during one hour. After, there is added 250 ml of 
EMEM medium supplemented with 20% of FBS, 2% of sodium pyruvate and 2% non-
essential amino acids. The solution is mixed overnight at 4°C. The solution is centrifuged 
at 5000g during two hours. The supernadant is aliquoted and conserved at 4°C. 
2.4 Immunofluorescence 
Twelve mm coverslips (Thermo Scientific, Braunschweig, Germany) previously washed 
with an alcoholic acidic solution (1 M of HCl (Sigma Aldrich, St.Louis, USA)  in 70% 
ethanol solution) were coated with 20 µg.ml-1 fibronectin (Promocell, Heidelberg, 
Germany) in PBS for 2 hours at 37°C and washed with PBS. Coverslips were distributed 
in 24-well plates. Cells were plated at cell density of 40,000 cells per well and cultured 
for 24 hours. When indicated cells were treated with drugs or the corresponding amount 
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of DMSO as control. After treatment, cells were fixed with a 3.7% paraformaldehyde 
(Electron Microscopy Sciences, Hatfield, USA) solution in PBS for ten minutes. Cells 
were washed three times for five minutes with PBS. Permeabilization was done using a 
0.1% (w/v) Triton X-100/PBS solution for two minutes. This step facilitates cellular 
membrane disruption and antibody access entry into the cells. To avoid unspecific 
interactions, cells were incubated with a 3% (w/v) BSA/PBS solution (Euromedex, 
Souffelweyrsheim, France) for one hour. Coverslips were then incubated with the primary 
antibody (diluted on 3% (w/v) BSA/PBS) for three hours at room temperature or 
overnight at 4ºC and followed by three washes (five minutes each) with PBS. Cells were 
then incubated for 45 minutes in the presence of the appropriate Alexa 488- , Alexa 546- 
or Cy5- conjugated secondary antibodies diluted in 3% (w/v) BSA/PBS solution 
containing DAPI (2.5 µg.ml-1). Cells were washed in PBS and the coverslips were 
mounted with fluorescence mounting medium (Dako, Carpinteria, USA), putting the cells 
in contact with the slide. All antibodies information and dilutions are presented on annex 
1. Optical section (750 nm Z-resolution) were imaged using an immersion oil (Type F 
Immersion liquid (Leica, Nanterre, France) HCX PL APO CS 11506188 objective 
(magnification of 63x, numerical aperture of 1.4, pinhole of 1.00 airy unit and a zoom of 
1.5) under the Leica TCS SPE II confocal microscope (Leica, Nanterre, France). Image 
analysis was performed using ImageJ software. The macro used for co-localization was 
JACOP, where the channels of interest are analyzed after performing a threshold to 
eliminate non-specific staining (background). The analysis determines the overlapping of 
the channels.  
2.5 Stochastic Optical Reconstruction Microscopy (STORM) 
STORM is a super-resolution microscopy technique that surpasses the diffraction limit 
by localization of individual fluorophores. Giving a lateral and axial resolution of 20 nm 
and 50 nm respectively, it allows the visualization of subcellular structures (141–143). 
STORM technique was used in our study to evaluate EGFR and β1 integrin co-
localization in endomembrane vesicles after gefitinib treatment. 
The immunofluorescence protocol of sample preparation was slightly modified for super-
resolution experiments. Microscope coverslips (18 mm in diameter) were coated with a 
mixture of fibronectin (20 µg.ml-1) and gold nanoparticles (3.8E+6 nanoparticles/ml, 100 
nm diameter) (Sigma Aldrich, St. Louis, USA). These gold nanoparticles are used for a 
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drift correction after image acquisition (143). Then cells were seeded on a top of coverslips 
at a cell density of 40,000 cells per well (using 12-wells plate). After treatment with 
gefitinib, cells were fixed, permeabilized and stained against EGFR and β1 integrin. All 
antibodies information and dilutions are presented in Annex 1. For super-resolution 
microscopy experiments nucleus were not stained with DAPI. Cells were kept in PBS at 
4°C until image acquisition. 
Super-resolution imaging was performed on an inverted microscope Nikon Eclipse Ti-E 
(Nikon, Amsterdam, Netherlands) equipped with 100x, 1.49 N.A. oil-immersion 
objective. Fluorescence signal was collected using an EM-CCD camera (Hamamatsu, 
Massy, France). Imaging and data analysis were done by a collaborator PhD student 
Oleksandr Glushonkov. 
2.6 Immunoblot Blot 
Cells were seeded in a 6-well plate at a density of 200,000 cells per well for 24 hours. 
The plates were placed on ice, the medium from the wells was removed and the wells 
washed with PBS (Euromedex, Souffelweyrsheim, France). The PBS was removed and 
the total cell lysate was obtained by adding 100 µl of lysis buffer: 100 mmol.l-1 NaF  
(Merck, Darmtadt, Germany), 1 mmol.l-1 Sodium orthovanadate  (Sigma Aldrich, 
St.Louis, USA), 1% Triton X-100 (Sigma Aldrich, St.Louis, USA), PBS (Euromedex, 
Souffelweyrsheim, France) 1X, 1 tablet/10 ml of Protease and Phosphatase Inhibitor 
EDTA-free (Thermo Scientific, Rockford, USA). Cell lysates were transferred to 1.5ml 
Eppendorf tube, vortex during 10 seconds and then placed on ice for 10 minutes. This 
process was performed three times. The lysates were then sonicated during 10 seconds at 
100% of power amplitude and the steps on vortex and ice were repeated. After a 13,000 
rpm centrifugation at 4ºC during 10 minutes, the supernatant was stored at -20ºC until 
used.  
Total protein concentration was evaluated by DCTM protein assay (Bio-Rad,Hercules, 
USA). This is a modified and faster version of the colorimetric Lowry assay, where the 
reaction only takes 15 minutes. First occurs a reaction between the peptide bonds of the 
protein with the copper ions in alkaline environment. Then this complex protein/copper 
reduces Folin reagent, oxidating aromatic residues (tyrosine and tryptophan) than become 
blue with a maximum absorbance at 750nm. A standard curve was made using BSA 
standart sets (Bio-Rad, Hercules, USA) from 0.2 to 2 mg/ml. The protein samples were 
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diluted 1:5 in cell lysis buffer. For the samples and standards it was performed duplicates, 
and followed the manufacture instructions. The plates were read on iMark Microplate 
Reader (BioRad, Hercules, USA). 
Before loading on the gel, the equivalent amount of proteins were diluted 1:1 in 2x 
Laemmeli Solution (Bio-Rad, Irvine, USA) mixed with β-mercaptoethanol (Roth, 
Karlsruhe, Germany) to have 10 µg of total protein in 13 µl. The samples were heated at 
96ºC during seven minutes to denature the proteins and allow their movement through an 
electric field due to the no neutralized negative charge from the amino acids.  
 
Proteins are separated based on their molecular weight on a sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). Electrophoresis was performed on a 4-
20% Tris-HCl CriterionTM Precast Gel (Bio-Rad, Irvine, USA) (which allows the 
separation of proteins between 2-400kDa) submerged in running buffer (10% TG 10X 
(Euromedex, Souffelweyrsheim, France), 0.5% of SDS>99% (Euromedex, 
Souffelweyrsheim, France)). The molecular weight marker Precision Plus Protein 
standards on 4-20%Tris-HCl CriterionTM Gel (Bio-Rad, Hercules, USA) was used to 
allow the following of the samples. The electric field applied was 240 V.  
Following this step, a wet transfer into a PVDF membrane (GE Healthcare Life Sciences, 
Freiburg, Germany) was performed. PVDF membranes compared to the nitrocellulose 
membranes have the advantage of later reprobing with an alternative antibody. The 
transfer was performed in a tank filled with transfer buffer (10% of TG 10X and 10% of 
absolute ethanol (Sigma-Aldrich, Steinheim, Germany)) for 32 minutes at 100 V.  
After the transfer was complete, the PVDF membrane was blocked with 5% (w/v) of non-
fat dried milk (Bio-Rad, Irvine, USA), diluted in washing buffer, for one hour at room 
temperature with agitation. The blocking step is crucial to prevent unspecific reactions 
from the primary antibody. The membrane was then incubated overnight at 4°C under 
agitation with the primary antibodies diluted in blocking buffer, followed by three washes 
of seven minutes using a washing buffer TBS/0.1% Tween 20 (Euromedex, 
Souffelweyrsheim, France). Secondary antibodies conjugated horseradish peroxidase 
(HRP) and diluted in blocking buffer were incubated for one hour at room temperature 
under agitation and followed by three washes of seven minutes using a washing buffer. 
Primary and secondary antibody references and dilutions are listed in detail on annex 1. 
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The antibody signal was revealed using Clarity TM western ECL substrate (Bio-Rad, 
Irvine, USA). This kit contains luminol and peroxidase, which in contact with HRP leads 
to emission of light. HRP when has its substrate peroxidase is able to oxidize luminol, 
creating them 3-aminophthalate dianion that emits light. Light emission was detected with 
LAS4000 imager (GEHealthCare) and quantify using ImageQuant analysis software 
(GEHealthCare). Data are presented as the mean +/- S.E.M of 3 independent experiments. 
2.7 EGFR uptake assay 
Cells were seeded at a cell density of 30,000 cells/wells on 12mm coverslips, previously 
coated with 20 µg.ml-1 fibronectin solution for 24h. Cells were then serum-starved during 
one hour, at 37ºC and 5% CO2, to remove all growth factors that can induce EGFR 
internalization, in a way to have the maximum number of receptors at the plasma 
membrane. Cells were placed on ice and washed with ice-cold Opti-MEM (Gibco, 
Paisley, UK). Cells were incubated at 4°C during 30 minutes with Alexa488-conjugated 
EGF (100 ng.ml-1) (Invitrogen, Carlsbad, USA) diluted on Opti-MEM. Cells were washed 
with Opti-MEM. Some coverslips were fixed at this step using paraformaldehyde 3.7% 
during 10 minutes and then washed three times with PBS. The other coverslips were 
incubated with 37ºC pre-warmed Opti-MEM and placed at the incubator (37ºC, 5% CO2) 
during one hour to allow the internalization of the ligands-bound receptors. Washing step 
with Opti-MEM was made, followed by fixation with paraformaldehyde 3.7% during 10 
minutes and washing with PBS.  
All coverslips were stained with DAPI, washed with PBS three times and mounted on 
slides using fluorescent mounting medium. Imaging was performed on the confocal 
microscope, in the mid-section of the cells. Image analysis to evaluate the number of 
vesicles was performed with ImageJ software using a homemade plugin (Romain 
Vauchelles, PIQ platform). Vesicles were counted after performing a threshold and was 
made a ratio between the number of vesicles and the number of cells (determined by the 
counting of the nucleus). 
2.8 Statistical Analysis 
Statistical analysis in more than two variables was done using one way ANOVA analysis, 
once the goal was to see if there was a significant difference between different conditions. 
Statistical analysis results were made using Bonferroni test with the software GraphPad 
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Prism. Statistical analysis in two variables was done using Student t-test. Data are 
represented as mean ± SEM (Standard error of the mean). The mean was obtained from 
independent experiments. The confidence interval of significance was stabilized at 95%. 
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3. Results 
Using cell evasion from 3D spheroids, our team previously showed that in U87 cells loss 
of α5 integrin expression are more sensitive to gefitinib treatment. Published works 
showed that EGFR endocytosis and trafficking  have been reported to have some 
influence in therapy resistance (65,144–146) and that integrin can regulate EGFR 
oncogenic activity during carcinoma invasion trought its trafficking. The aim of my 
master project was to determine if the endocytic pathway is involved in the integrin-
mediated resistance to gefitinib. 
3.1 Dynamin inhibition reverts negative effect of gefitinib in cell evasion  
 
To determine if endocytic events are related with gefitinib resistance, endocytosis was 
blocked using pharmacacological inhibitors of dynamins. Dynamins (fig.3.1) are  GTPase 
proteins involved in the budding of endocytic vesicles in the main endocytosis pathways, 
including clathrin-dependent route (fig.3.2). This route is described to be used by EGFR 
and integrins (45,96,132,147). Dynamins were blocked using two chemical inhibitors of 
its GTPase activity: dynasore (IC50 80µM) which is a non competitive inhibitor inhibiting 
both dynamins (1 and 2) and dyngo4-a (IC50 16µM), which bind to an allosteric site on 
the G domain and is more potent on dynamin 1 (0.4µM) than on dynamin-2 (3µM). There 
were evaluated using curve dose effect ranging from 6 to 50 µmol.ml-1 for Dynasore and 
from 10 to 80 µmol.ml-1 for Dyngo4-a.  (45,96,132,147).  
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Figure 3.1: Dynamin struture and its role in membrane fission. A-  Domain organization in human 
dynamin, where the number correspond to amino acid position on the gene.  G domain is involved 
in GTP binding and consequent GTPase function, Middle and GED are involved in dynamin 
dimerization and oligomerization, PH and PRD domains are involved in dynamin interactions 
with other proteins.  B – Mechanistic how dynamin after polymeration and consequent GTP 
hydrolysis leads to membrane fission. Adapted from (140).  
 
 
Figure 3.2: GTPase function of dynamin in clathrin-mediated endocytosis. After GTP binding, 
dynamin assembly in the neck of clathrin pit. GTP hydrolysis mediates dynamin conformation 
change that leads to vesicle fission. Adapted from (148).  
 
 
 
A 
B 
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Resistance to gefitinib was evaluated using cell evasion from a 3D small cluster of cells 
(spheroid). The assays were performed in two different cell lines (U87 α5+ and U87 α5-
). The drugs were incubated alone or in combination with gefitinib during the 18 hours of 
cell evasion. The results are represented on figures 3.3 and 3.4 for dynasore, 3.5 and 3.6 
for dyngo-4a.  
When dynasore was incubated alone, we observed a significant decrease of cell evasion 
(number of cells out the spheroid) on the two highest concentrations (25 and 50 µmol.ml-
1) (for 25 µmol.ml-1 U87 α5+ 424.5±42.65, U87α5- 352.3±41.83; for 50 µmol.ml-1 U87 
α5+ 342.0±24.55, U87α5- 324.2±33.95) in both cell lines compared with control cells 
(U87 α5+ 493.6±27.41, U87α5- 449.0±29.70) but no impact in the number of evading 
cells at lower concentrations (fig. 3.3, 3.4).   
In agreement with previous results from the team, gefitinib used alone inhibited cell 
evasion in both cell lines but with more efficacy on U87a5- cells (133.1±11.34) than on 
U87a5+ (255.7±24.79).    
Surprisingly, we observed that dynasore (12µM) completely blocked gefitinib-mediated 
evasion inhibition. Indeed, at a concentration of 12 µM of dynasore, we observed a 
significant increase in the number of evading cells when compared to gefitinib alone, both 
in U87a5+ cells (425.7±23.71 and 255.7±24.79, respectively) and in U87a5- cells 
(394.9±26.02 and 133.1±11.34, respectively). This event was statistically significant with 
the two lowest concentrations of dynasore (6 and 12 µmol.ml-1) plus gefitinib (fig. 3.3, 
3.4). As similar results were observed in both cell lines, this suggest that evasion 
stimulation by dynamin inhibition is α5 integrin- independent. Thus, dynamin inhibition 
by dynasore in low concentration has no impact on cell evasion of controlled cells but 
prevent gefitinib-induced inhibition of cell evasion. These results revealed an important 
function of dynamin in the activity of gefitinib.  
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As pharmacological inhibitors in general and dynasore in particular have unspecific 
effects (149), we control the involvement of dynamin in gefitinib-mediated inhibition 
using another dynamin inhibitor, dyngo-4a (fig. 3.5, 3.6). 
When cells were incubated with gefitinib alone, there was a significant decrease of the 
number of cells that goes out of the spheroid in both cell lines (fig. 3.5, 3.6). This decrease 
was more accentuated in the α5 - cell line (140.5±13.14) than in U87a5+ (173.8±12.14) 
compared with the control (U87 α5+ 372.3±17.30, U87α5- 477.7±23.68), as described 
before (fig. 3.6).  
When cells were incubated with dyngo-4a and gefitinib there was observed an increase 
of cell evasion compared with only gefitinib incubation (for 10 µmol.ml-1 U87 α5+ 
457.7±29.83, U87α5- 290.6±37.97; for 20 µmol.ml-1 U87 α5+ 361.8±22.33, U87α5- 
348.3±35.85; for 40 µmol.ml-1 U87 α5+ 328.8±16.77, U87α5- 443.7±38.75) (fig. 3.5, 
3.6). This event was statistically significant comparing gefitinib incubation with all 
concentrations of dyngo-4a except with the highest one. This phenotype occurred in both 
cell lines, demonstrating being α5 integrin independent. At 80 µmol.ml-1 of dyngo-4a 
plus gefitinib the cell evasion decreases comparing with the control but still is higher than 
the gefitinib condition (U87 α5+ 247.2±33.16, U87α5- 110.6±19.42). This decrease was 
more accentuated in α5 – cell line (fig.3.6). 
Altogether, using two different pharmacological inhibitors, we showed that dynamin is 
involved in the gefitinib-mediated inhibition of U87 cell evasion regardless the a5 integrin 
expression level. This suggest that the endocytic pathway play a critical role in gefitinib 
mediated inhibition.  
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Figure 3.6: Cell evasion on U87 α5- under treatment with dygo-4a and gefitinib. U87 α5- spheroids were seeded on 
fibronectin-coated surface in the presence (20µM) or the absence of gefitinib and various concentration of dyngo-
4a for 18 hours. A-J Phase Contrast images of spheroids under different incubation conditions (Scale bar 200 µm): 
A- Control, B- Dyngo-4a 10 µmol.ml
-,1
, C- Dyngo-4a  20 µmol.ml
-,1
, D- Dyngo-4a  40 µmol.ml
-,1
, E- Dyngo-4a  80 
µmol.ml
-,1
F-J – Gefitinib 20 µmol.ml
-,1
 (F-alone, G- Dyngo-4a  10 µmol.ml
-,1
, H- Dyngo-4a  20 µmol.ml
-,1
,I- Dyngo-
4a 40 µmol.ml
-,1
 , J- Dyngo-4a 80 µmol.ml
-,1
). K, L- The number of evading cells was quantified after DAPI-
labelling of their nucleus and data were expressed as the ratio of evading cells compared to control (DMSO-treated) 
cells. Histograms represent mean±SEM of 3 independent experiments.  Statistical analysis was made using ANOVA 
*p<0.05; **p<0.01; ***p<0.001; **** p<0.0001 
U87 α5- Control Gefitinib 
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3.2 Endocytosis is important in gefitinib treatment  
 
As dynamin inhibition suggests a role for endocytosis in gefitinib effect, we thus seek to 
verify the impact of gefitinib on EGFR distribution in U87 cells. To this end, we 
performed confocal immunofluorescence microscopy against EGFR and one marker of 
early endosomes (EEA1). EEA1 is essential for early endosomes homotypic fusion being 
one of Rab5 protein effectors (150). The cells were treated with 20 µmol.ml-1 of gefitinib 
in a time course experiment (zero to seven hours). In control U87 cells (fig.3.7 and 3.8), 
EGFR is localized mainly in the plasma membrane, while EEA1 is present in classical 
cytoplasmatic small vesicles. Only few early endosomes were immunolabelled by anti-
EGFR antibodies. After gefitinib treatment, the presence of EGFR in early endosomes 
increased with time. This result demonstrates that gefitinib induces the localization of 
EGFR in early endosomes. We quantify the co-localization between EGFR and EEA1 at 
the different times using Pearson’s correlation coefficient. As showed on figure 3.9, 
colocalization between the two proteins increased with time, in both cell lines (for 1 h 
U87 α5+ 44%, U87α5- 38%; for 2h30 U87 α5+ 68%, U87α5- 48%; for 7h U87 α5+ 68%, 
U87α5- 43%). Importantly, similar results were obtained in U8 a5+ and U87 a5-, 
indicating that gefitinib induced EGFR endocytosis independently of α5 integrin 
expression level. 
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3.3 Gefitinib induces EGF uptake and dynasore impaired this phenotype 
In order to determine if dynasore could impege gefitinib-mediated EGFR endocytosis, we 
then determine the influence of gefitinib and dynasore on ligand-induced EGFR 
internalization using fluorescent-tagged EGF.  
To this end serum-starved U87 a5+ and U87 a5- cells were incubated at 4°C (a situation 
where endocytosis does not occur) in the presence of EGF-Alexa 488 (100 ng.ml-1). Cells 
were then whashed and kept at 4°C (negative control) or placed at 37°C for various period 
of times (a situation where endocytosis occurs in normal conditions). In figure 3.10, at 
4°C the staining is mainly at the plasma membrane, even if there are some cytoplasmic 
background. After one hour at 37°C, EGF is founded inside of the cells, in small vesicles. 
To assess for the impact of gefitinib on EGFR internalization, we compared EGF uptake 
on control and gefitinib-treated U87 a5+ and U87a5- cells (Fig. 3.11), the number of 
EGF-positive vesicules were quantified using a home-made ImageJ plugin (Fig. 3.12).  
As shown here, gefitinib significantly increased EGF internalization in both cells lines 
(for U87α5+ 12.52±2.281, for U87α5-10.14±1.868) compared with the positive control 
(for U87α5+ 8.071±0,7432 for U87α5-5.355±0.5567). We then measured EGF uptake on 
cells treated with dynasore. In the absence of gefitinib, dynasore (50µM) clearly inhibits 
EGF internalization in U87a5+ cells (4.384±0.9250) but not in U87a5-(6.187±0.7204). 
When cells are treated with 50 µM dynasore and gefitinib, dynamin inhibition 
significantly reduced gefitinib-mediated EGF endocytosis (for U87α5+ 5.211±0.8251, 
for U87α5- 4.344±0.6354). This impairment is visualized in both cell lines and so it is α5 
integrin independent. This result shows a similar pattern to the one obtained in cell 
evasion assay. Together with the evasion assays, our experiments indicate that blocking 
dynamin-mediated endocytosis of EGFR prevent this action of gefitinib on cell evasion, 
independently of a5 integrin expression level. 
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Figure 3.10: Negative (4°C) and Positive (37°C) controls of EGF uptake assay. Serum-starved 
cells were incubated with Alexa 488-EGF (100 ng.ml-1) at 4°C for 30 minutes. Cells were then 
placed at 37°C for one hour. to allow internalization or kept at 4°C as control. At the end of the 
time course, cells were fixed and stained with DAPI and confocal images were performed Scale: 
20 µm 
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Figure 3.11: EGF uptake after treatment with dynasore and/or gefitinib. Serum-starved cells were 
incubated with Alexa 488-EGF (100 ng.ml-1) at 4°C for 30 minutes. Cells were then placed at 
37°C with 20 µM of gefitinib and/or 12 or 50 µM of dynasore for one hour to allow EGF 
internalization. At the end of the time course, cells were fixed and stained with DAPI and confocal 
images were performed Scale: 20 µm 
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Figure 3.12:  Quantification of EGF uptake after treatment with dynasore and/or gefitinib. After 
fixation, confocal images were analysed with a home-made ImageJ plugin to quantify the number 
of EGF-containing intracellular vesicules per cells. Histograms represent mean±SEM of at least 
12 cells from 2 independent experiments.  Statistical analysis was made using ANOVA *p<0.05; 
**p<0.01; ***p<0.001 
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3.4 β1 integrin and EGFR co-localized in endomembranar strutures after gefitinib 
treatment. 
In our cell evasion assays, α5 expression is a resistant factor to gefitinib. However, we 
observed that gefitinib can induce EGFR internalization independently of integrin 
expression level. It has been published that α5 integrin can traffic with EGFR to promote 
carcinoma cell invasion (131,151). Our interpretation is that α5β1 integrin may impact on 
EGFR trafficking and function during membrane trafficking after endocytosis. We thus 
first seek to determine if β1 and α5 integrins were also internalized with EGFR after 
gefitinitb treatment. To this end we used confocal immunofluorescence microscopy. It 
can be observed (fig.3.13) that β1 integrin and EGFR in control cells are mostly present 
at the plasma membrane. Surpringly, after gefitinib treatment, β1 integrin is also 
internalized and found in EGFR-positive endosomes. These results occured in both cell 
lines, U87 α5+ and U87 α5-. Related to α5 integrin (fig.3.14), the integrin is mainly 
localized at cell/ECM adhesion structures in U87 α5+, while is almost inexistent in the 
U87 α5- cells. In focal adhesion level, co-localization between active α5 integrin and 
EGFR did not occur. After gefitinib treatment, EGFR and α5 integrin are internalized and 
in some cases found in the same vesicules.  
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Figure 3.13: β1 integrin and EGFR are co-internalized after gefitinib treatment. Confocal images of U87 
cells α5+ and α5- in the absence (Control) and presence of 20 µmol.ml-1 gefitinib (Gef). Cells were fixed, 
permeabilized and stained against β1 integrin and EGFR. The merge of the two images can be seemed on 
right column (Merge). Zoom in images was 3 x. Scale: 20 µm 
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Figure 3.14: α5 integrin and EGFR are co-internalized after gefitinib treatment in U87α5+.Confocal images 
of U87 cells α5+ and α5- in the absence (Control) and presence of 20 µmol.ml-1 gefitinib (Gef). Cells were 
fixed, permeabilized and stained against α5 integrin and EGFR. The merge of the two images can be seemed 
on right column (Merge). Zoom in images was 3 x. Scale: 20 µm 
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Due to diffraction-limited resolution, confocal fluorescence microscopy can only 
distingue two proteins that distant from each other more than 300 nm (x-y plane). To 
overcome this fault, we used a super-resolution technique, PALM- STORM imaging, in 
order to determine with more precision, the proximity between β1 integrin and EGFR 
(spatial resolution around 20-30 nm in x-y plane). After gefitinib treatment (fig.3.15), 
both proteins are closed to each other in endosomal compartment. This experiment 
demonstrates that  after geftinib treatment, β1 integrin and EGFR may physically be in 
endosomes. 
  
Figure 3.15: β1 integrin and EGFR are co-localized after gefitinib treatment. PALM-STORM 
images of U87 cells α5+ in and presence of 20 µmol.ml-1 gefitinib. Cells were fixed, 
permeabilized and stained against β1 integrin and EGFR. The merge of the two images can be 
seemed on right side (Merge). Zoom in images was 3 x.  Scale: 200 nm 
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3.5 Gefitinib-induced EGFR and β1 integrin internalization occurs in others 
glioma cell lines 
To verify what occurs in others glioma cell lines, protein levels of α5 integrin and EGFR 
and gefitinib induced endocytosis were evaluated.  First of all, α5 integrin and EGFR 
protein levels were analyzed to confirm the presence of these proteins in glioma 
phenotype. It was demonstrated that different cell lines presented different protein levels 
patterns (fig. 3.16 and table 3.1). There are two cell lines with high levels of α5 integrin 
(LN443 and U87) and three cell lines with high levels of EGFR (SF767, SF763 and T98). 
Both SF 767 and SF 763 present low levels of α5 integrin.  LN319 presents low levels of 
both proteins.  
Confocal microscopy was performed in different glioma cell lines after gefitinib 
treatment (fig.3.17 and 3.18). In control condition, EGFR and β1 integrin are mainly 
localized in the plasma membrane.  After treatment with 20 µmol.ml-1 of gefitinib during 
24 hours, there were also verified internalization of EGFR and β1 integrin in diverse 
glioma cell lines. The occurence of internalization is described on table 3.1.  These results 
provide information for the strong contribution of gefitinib in this phenotype in glioma 
cells, being this α5 integrin independent since the strong internalization occured in cell 
lines with low α5 integrin level.  
Figure 3.16: Protein expression of α5 integrin and was analyzed by immunoblotting using 
GAPDH as a loading control.   
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Table 3.1 -  Characteristics of different glioma cell lines. Protein expression of α5 integrin and 
was analyzed by immunoblotting using GAPDH as a loading control. Each value represents the 
mean±SEM, n = 3. β1 Integrin and EGFR internalization after gefitinib treatment was evaluated 
with confocal immunofluorescence microscopy 
 Protein expression level Internalization 
Cell line α5 integrin EGFR β1 integrin EGFR 
LN443 4.18±0.79 0.79±0.53 Medium Weak Medium Strong 
LN229 0.20±0.22 0.31±0.32 Strong Strong 
SF767 Below 0.01 1.08±1.09 Strong Strong 
U373 0.02±0.01 0.38±0.23 Medium Medium 
T98 0.10±0.09 1.81±1.40 Medium Strong Strong 
LN319 0.05±0.04 0.07±0.05 Weak Medium 
LNZ308 0.53±0.45 0.86±0.60 Medium Medium Strong 
SF763 Below 0.01 2.24±1.36 Strong Strong 
U87 ATCC WT 4.83±2.38 0.77±0.52 Strong Strong 
U87 ATCC α5- 0.11±0.04 0.85±0.67 Medium Strong Strong 
U87 ATCC α5+ 4.24±1.94 1.17±0.86 Strong Strong 
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Figure 3.17: EGFR and β1 integrin localization in absence (Control) and presence (Gef) of  
20µmol.ml-1of gefitinib. Cells were fixed, permeabilized and stained against EGFR and β1 
integrin. The merge of the two images can be seemed on the right column (merge). Zoom in 
gefitinib images was 3 x. Scale: 20 µm 
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Figure 3.18: EGFR and β1 integrin localization in absence (Control) and presence (Gef) of  
20µmol.ml-1of gefitinib.Cells were fixed, permeabilized and stained against EGFR and β1 
integrin. The merge of the two images can be seemed on the right column (merge). Zoom in 
gefitinib images was 3 x. Scale: 20 µm 
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4. Discussion 
Glioblastoma is the most aggressive brain cancer, being characterized by its resistance to 
therapy.EGFR is involved in gliomagenesis, being  a very interesting therapeutic target.  
Anti-EGFR targeted-therapies are effective in other cancers. But in glioblastoma the 
clinical trials with antibodies and TKI failed. Until now, there is not a consensus related 
to predictive factors in EGFR-targeted therapies, even the co-existence of the mutated 
EGFRVIII and PTEN deletion is not a predictive factor (92). To try to uncover the nature 
of this resistance, the group started studying the relationship between EGFR and α5 
integrin. Indeed, integrins are known to enhance oncogenic EGFR function and can 
trigger resistance to anti-EGFR therapy in carcinoma preclinical models (131). α5 
integrin was described as a diagnostic, prognostic and predictive factors and is a new 
pertinent therapeutic factor in glioblastoma (108,113,116,117). α5 integrin was also 
associated with migration in GBM (114,115).  So, migration and its is important to study 
regulation of migration and invasion in GBM.  Co-trafficking between EGFR and α5β1 
integrin are described during carcinoma invasion (131). 
The objective I had was to determine if endocytic pathway is important for resistance to 
a clinical approved anti-EGFR TKI (gefitinib) during GBM cell dissemination.  
During my master, using 2 differents pharmacological inhibitors of dynamin, a critical 
protein of clathrin-dependent endocytosis, we completely blocked gefitinib-induced 
inhibition of cell evasion from 3D spheroids. This observation was made either on cell 
expressing high or low level of α5 integrin. By confocal microscopy we showed that 
gefitinib-treatment induced the EGFR endocytosis. EGFR endocytosis was independent 
of α5 expression level. Using EGF-induced internalization we confirmed that gefitinib 
enhances EGFR endocytosis and that dynamin inhibitors prevent EGFR internalization. 
We hypothesis thus that, when endocytosis is impaired, cells become resistant (with a 
more evading behaviour) to gefitinib independently of α5 level. Gefitinib-mediated 
EGFR endocytosis happen together with α5β1 integrin endocytosis. And we used super-
resolution microscopy (PALM-STORM) to show that the two proteins may physically 
interact in endosomes. Thus, we speculate that when endocytosis occured normally, α5β1 
integrin may impact on EGFR trafficking and function during membrane trafficking 
downstream of endocytosis to confer resistance towards gefitinib treatment. 
Integrin alpha5beta1 and resistance to cancer therapies 
 
68 
 
In the endocytic trafficking, the first step is the protein internalization. Different pathways 
are described for internalization, the clathrin-dependent pathway isthe most common for 
both EGFR and integrin.  
The clathrin-mediated endocytosis has the following steps: putative nucleation, cargo 
selection, clathrin coat assembly, vesicle scission, uncoating and recycling of clathrin. 
Putative nucleation corresponds to the formation of a pit (membrane invagination) that 
will be recognized by protein such as Eps15. Eps15 binds to EGFR, being involved in the 
receptor endocytosis. The cargo selection is mediated by AP2, another protein that 
interacts with EGFR, to recruit it for the pit. When cargo is bound to the pit, clathrin stars 
to assembly, being recruited by AP2 to the plasma membrane. Proteins in the neck of the 
vesicle recruit dynamin. Dynamin is a GTPase protein that allows membrane fission. 
After vesicle detachment from the membrane clathrin starts to disassemble. 
The role internalization in gefitinib activity could be studied through the manipulation of 
diverse proteins like clathrin and dynamin. Dynamin was the chosen one, because it 
affects only the internalization process and not the plasma membrane invagination and 
protein contain. It was already described the need of clathrin microdomain for EGFR 
signaling pathways independetly of receptor endocytosis (152). Also, dynamin is 
involved in more than one endocytic pathways, and the goal of this objective was not to 
specifically characterize the endocytic mechanism but only see its role in gefitnib 
treatment.  
Dynamin is a GTPase protein involved in cell membrane remodeling. Mammalian 
dynamin family has three isoforms, which are very homologous between each other but 
with different expression patterns.  Dynamin 1 is expressed only in neurons, dynamin 2 
is ubiquitously expressed and dynamin 3 is present in the brain and testis. There are 
different models to explain membrane fission but all are mechanoenzyme- and GTPase 
activity-dependent. The GTP hydrolysis provokes a conformation change of dynamin, 
generating forces that results in fission by constriction or stretching (147,153).  
To impair the role of dynamin, we used two chemical inhibitors: dynasore and dyngo-4a. 
Both dynasore and dyngo-4a block dynamin GTPase activity after the recruitment and 
self-assembly. They are both small interfering molecules that allow fast impact on 
biological processes, being also most of the time reversible. This confers an advantage of 
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chemical inhibitory molecules over dominant-negative mutants or dynamin knockdown 
by small interfering RNA (siRNA) (153).  
Dynasore is a reversible noncompetitive inhibitor of GTPase activity of dynamin, 
preventing the scission of vesicles from the plasma membrane. Dynasore inhibits 
dynamin 1 and 2 regardless of their assembly state with GTP, so it interferes with the 
catalytic step. At 80µM, dynasore seems to inhibit also the mitochondrial dynamin 
Drp1(153). Dyngo-4a is a more potent dynamin inhibitor, being 37 times stronger that 
dynasore, and also less toxic to the cells.  Dyngo-4a shows more selectivity towards 
dynamin 1 and it binds to allosteric site of G domain. The usual concentrations used for 
these two inhibitors are 80 µM for dynasore and 30 µM for dyngo-4a. Endocytic blockage 
of dynasore was maximum at 80 µM and half-maximum at 30 µM. However, these 
concentrations were often used serum-free medium and for short period of times (1-3 
hours). To avoid dynasore unspecific effects and extreme toxicity (due to also incubation 
with gefitinib in some conditions), we performed a dose effect between 6 and 50 µM 
(154).  Dyngo-4a is known to be more effective and less toxic than dynasore. But it also 
has a higher affinity towards dynamin 1 (only expressed in brain) versus dynamin 2 
(ubiquitous expressed). Dynamin 2 is involved in cell migration in glioblastoma and 
others cancers (155–158). To try to potentiate also dynamin 2 inhibition, to study the toxic 
effects and possible off targets of the drugs and/or dynamin inhibition, there were used a 
dyngo-4a concentrations range between 10 and 80 µM. But it is important to have in mind 
that these results were obtained while inhibiting dynamin with chemical inhibitors that 
have some disadvantages. A chemical inhibitor unables one protein function while 
leaving unchanged all others. These inhibitors, dynasore and dyngo-4a, were reported to 
have some off targets (149,159). Using dynamin triple knock out mice were revealed off 
targets of Dynasore, not related with dynamin, such as inhibition of both fluid-phase 
endocytosis and peripheral membrane ruffling. These inhibitors are involved in inhibition 
of membrane ruffling and it can happen by the destabilization of F-actin. Both inhibition 
of fluid-phase endocytosis and membrane ruffling are related since in the first the 
extracellular material is engulfed by plasma membrane extensions. Dynasore seems to 
affect in a dynamin-independent way the lipid rafts, by reducing cellular levels of 
cholesterol but also turning its distribution more dispersed on plasma membrane. This 
phenotype can also be involved in the ruffling. Dynamin is involved in the delivery of 
cholesterol from endosomal compartment to endoplasmic reticulum, but its 
Integrin alpha5beta1 and resistance to cancer therapies 
 
70 
 
downregulation using RNA interference does not give the same phenotype as dynasore 
regarding to cholesterol (149,159,160). Also chemical inhibitors have some troubles 
regarding stability and efficiency. Dynasore was reported to become unstable with time 
and to lost activity with high cellular density (more than 70% confluency), with the use 
of detergents such as Tween and with the use of serum (153,161). Also, due to possible 
non-specific effect of dynasore and dyngo-4a, dynamin 1 and 2 depletion by siRNA is 
required to confirm the role of dynamin proteins in gefitinib activity. 
The biological assay used to evaluate the gefitinib resistance was the cell evasion from a 
small cluster of cells (spheroids). Spheroids are widely used to better characterize cellular 
events then the normal 2D cell culture. Spheroids assays resemble some physiological 
characteristics present in vivo such as cell-cell interactions, cell-ECM interactions, and 
the accessibility in gradient to oxygen, nutrients, drugs and signals (162,163). We focused 
on cell evasion because cell migration is one of the main characteristics of GBM and also 
previous work from the team showed that α5 expression had no impact on gefitinid 
inhibitory activity on cell growth and survival (data not shown). GBM are highly invasive 
tumors. This glioma cell migration and invasion make difficult the total tumor resection 
(first therapy line in this cancer). Also, migrating cells are more resistant to therapy (164). 
Migration was studied by plating spheroids on fibronectin-coated surface. Fibronectin 
was used as ECM protein because it was described to be overexpressed in glioblastoma 
and it is the ligand of α5β1 integrin. The activation of α5β1 integrin after fibronectin 
binding was described as a activator of beta-catenin pathway that leads to migration in 
glioma cells (113,165).  Migration can also be evaluated using other assays, using mainly 
monolayer culture. It can be evaluated by a boyden chamber anda wound healing assay 
for example (166).  
We first showed that dynamin inhition completly blocked gefitinib action on U87 cells, 
whatever the level of α5 integrin expression (Figures 3.3-3.6). This result suggest that 
endocytosis is required for an efficient inhibition of EGFR. Dysregulation of EGFR 
trafficking is involved in therapy resistance toward anti-EGFR TKI (167,168). In our 
experience, after plating the spheroids on fibronectin, there were incubated with dynamin 
inhibitors, gefitinib or both during almost one day.  When dynasore was incubated alone, 
it affected cell evasion only at the highest concentrations studied (25 and 50 µM) while 
dyngo4-a did not affect cell evasion whatever the concentrations used. Since dyngo 4-a 
is more potent than dynasore and it was used at higher concentrations, it can be supposed 
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that the decrease of cell evasion observed in dynasore was due to its toxicity or specific 
off-target effects of this drug. When cells were incubated with the lowest concentrations 
of dynasore (6 and 12 µM) and gefitinib, there were observed a reversion of the cell 
evasion impairment caused by gefitinib.  This event was α5 integrin independent. In the 
highest concentrations of dynasore the cell evasion was slightly higher than gefitinib 
alone or in the same range. Related to dyngo-4a all concentrations revert gefitinib-induced 
inhibition of cell evasion, with more strength at the lowest concentrations. Like for 
dynasore, this phenotype was α5 integrin independent. To complete this work, we should 
evaluate the toxicity of the drugs by studying the cell viability with MTT test or trypan 
blue exclusion test or by studying cell death by annexin V/ propidium iodide assay.  
To confirm that endocytosis is important in gefitinib treatment, we evaluated if EGFR is 
present in early endosomes, that are the first endosomal vesicles after internalization. The 
nature of the vesicle was verified using confocal immunofluorescence microscopy with 
EGFR and EEA1 antibodies. EEA1 as described above is an early endosome marker. We 
also performed co-localization quantification using the macro JACOP by overlapping the 
channels of EGFR and EEA1 before and after gefitinib treatment.  We observed a strong 
increase in the co-localization between these two proteins after gefitinib treatment. This 
result clearly show that gefitinib stimulate endocytosis in U87 cells. 
To confirm that dynamin inhibitors trigger resistance to gefitinib by control of endocytic 
pathway, we used ligand-bound EGFR internalization assay. The data presented on 
figures 3.11 and 3.12 confirmed that gefitinib stimulated EGFR dynamin-dependent 
endocytosis and that this event occurs independently of the α5 integrin level of 
expression. Moreover, dynasore efficiently blocks the increased EGF uptake induced by 
gefitinib. 
The assay used was based on the internalization of Alexa 488-EGF. EGF bounds to 
EGFR, inducing its endocytosis as described for ligand-bound receptor (47). Before 
starting the assay, cells were serum-starved to remove all growth factors present in the 
medium solution. This allows themaximal expression of EGFR at the plasma membrane 
level. This experiment has its faults that can be improved. On cells kept at 4°C, EGF 
localization was mainly at the plasma membrane. But we also observed some intracellular 
fluorescence. The problem likely came from autofluorescence of the cell becauseEGF-
Alexa 488 concentration was quite low. To improve this, we will need a control with 
unlabeled cells and also to increase EGF-Alexa 488 concentration. Dynasore alone did 
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not have an effect in control untreated cells. These is surprising because in the literature 
ligand-induced EGFR endocytosis is dynamin dependent (169). However, in these 
experiences higher concentration (80µM) of dynasore were required to effectively block 
EGF internalization. Also, it should be used a positive control for clathrin-dependent 
endocytosis as transferrin, a wide used control (170). To remove non-endocyitozed EGF 
and enhance quantification of endocytosed EGFR, it should be made an acidic wash after 
the incubation at 37°C (for example sodium acetate buffer, pH 4.5). This step does not 
affect EGFR properties (171,172). The protocol needs to be optimized to the cell line used 
due to all stresses (serum-starvation, differences of temperatures). There is also an 
alternative technique to quantify ligand-induced endocytosis of EGFR based on 
biochemical approaches (131). It is important to have in mind, that in here it is only 
evaluated the ligand-bound EGFR internalization, but gefitinib can also induce 
unbounded-EGFR internalization. To verify this the same experiment can be reproduced 
using an anti-human EGFR antibody directly conjugated with fluorophore. With this type 
of protocol, EGFR internalization is stimulated by ligand binding. It still needs to be 
evaluated the role of dynamin inhibition on EGFR gefitinib-induced. To this end EGFR 
distribution can be analyzed on cells treated by gefitinib and dynamin inhibitors.The 
internalization profiling can be done with a time course experiment on living cells. To 
this end cells expressing EGFR-GFP are treated with gefitinib and live imaging can be 
performed with Total Internal Reflection Fluorescence Microscopy. This technique only 
allows the visualization of a limited sample region (until 200 nm of depth), allowing the 
visualization of the plasma membrane and the first steps of internalization processes.  
Because α5 expression protects cells from gefitinib, we thought that this must happen 
after the endocytosis. We thus analyzed α5 and β1 distribution in cells treated with 
gefitinib.  We clearly found by confocal immunofluorescence microscopy that β1 integrin 
is internalized after gefitinib treatment and found in EGFR-positive endosomes. This co-
internalization happened in both U87 α5+ and U87 α5- cells, demonstrating it is 
independent of α5 expression level. To better assess if α5 expression affect gefitinib-
induced endocytosis of  β1, we should performed antibody-mediated integrin endocytosis 
assays as performed with EGFR. Also we should performed triple staining against EGFR, 
β1 integrin and early endosome markers (EEA1 or Rab5) and focal adhesion markers 
(paxillin, FAK), to compare the co-localization of the 2 receptors at the plasma membrane 
and in the endosomes. This can be achieved using labelled-primary antibodies. It can be 
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done also by expressing EEA1-GFP or paxillin-GFP and performing indirect 
immunofluorescence for the others integrin and EGFR. The other proteins should be 
labelled using fluorophores with compatible fluorescent spectra than GFP (excitation 
peak at 395 nm, emission peak at 488nm). 
Measurement of protein proximity and thus possible physical interaction is crucial for 
biological systems knowledge. Multi-protein complexes are around 20-50 nm of 
diameter. This value is below the optical resolution limit (minimal distance between two 
points so they can be visualized independently) obtained with conventional fluorescence 
microscopy. Usually, the technique used is fluorescence microscopy imaging by 
overlapping images obtained for each protein of interest. Proteins are labeled with 
fluorescent-label antibodies, with different excitation spectra. After imaging acquisition, 
channels are overlap and it is formed a composite image. Unfortunately, diffraction-
limited resolution of this technique only allow the discrimination of two different proteins 
at the minimal distance between each other of 200-300 nm in the xy-plane and 500-700 
nm in  the z-axis (141,142,173). 
To overcome this problem, super resolution techniques such as stochastic optical 
reconstruction microscopy (STORM) were built. In this technique photo-switchable 
fluorophores are sequentially activated, imaged and deactivated, in order to determinate 
with high precision the position of the fluorophore in a given moment. In the end, all the 
positions acquired allow a resolution of 20-25 nm along the xy-plane and less than 50 nm 
in the z-axis (fig.4.1) (174). 
With STORM it could be observed that after gefitinib treatment, EGFR and β1 integrin 
are both localized in vesicle structures, being closed to each other. This in support of a 
physical interaction between the 2 proteins in the endosomes. Another techinique of 
choice to measure protein interaction is FRET (Fluorescence resonance energy transfer). 
FRET is based on a energy transfer system between two chromophores. The donor is 
excited with a lower energy unable to excitate the acceptor. When the two proteins are 
apart, the signal obtained is from the donor. When they are closed to each other, occurs a 
energy transfer and in thi time is the acceptor that emits light (175,176).    
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Figure 4.1: STORM versus diffraction-limited imaging techniques. When proteins that are 
directly associated (A) or located less than 20 nm apart (B) are indistinguishable by both types of 
techniques. However, STORM is able to distinguish proteins located over than 20 nm apart (C, 
D), while diffraction-limited imaging techniques are only able to distinguish when this distance 
is over 300 nm (D). Adapted from (173). 
 
We also observed that EGFR is internalized after gefitinib treatment in different cell lines. 
In most of them, there is also β1 internalization. This phenotype seems to be α5 
independent as cell lines with low integrin expression levels, seem to have strong 
internalization (SF763 and SF767 for example). Internalization characterization was 
made by evaluating in different cells, the occurrence or not of internalized proteins 
(founded inside of the cytoplasm in endomembranar-like strutures). More rigourous 
image analysis are required to confirmed these results, as describe above. In this 
experiment, we used the same gefitinib incubation condition as the one used with U87 
cell line. But the cells are different, so it should be done a gefitinib dose effect on these 
cell lines regarding concentration and time of incubation.  This evaluation should contain 
a toxicity test and an internalization profiling. For toxicity it can be studied the cell 
viability by MTT test or trypan blue exclusion test or the cell death by annexin V or 
caspases levels, in different drug concentrations and time of incubation. Cell evasion in 
these cell lines still needs to be evaluated, so it can be made a correlation between EGFR 
internalization and gefitinib treatment. 
It can be concluded that during gefitinib treatment, EGFR endocytosis occurs and cell 
evasion decreases. Integrin α5 influences the response profile of cells to gefitinib, since 
its downregulation sensitizes the cells to treatment, but do not have influence in the 
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endocytic phenotype. Dynamin inhibitors do not influence cell evasion alone, but, 
impaired gefitinib-induced inhibition of U87 cell evasion. Dynamin inhibitors impair 
gefitinib-induced endocytosis. Endocytosis was reported to be a novel therapeutic target. 
In several studies, growth factor receptor endocytosis was reported to not be the signal 
attenuation mechanism. Endosomal EGFR signaling was able to activate the major 
signaling pathways and suppress cell death after serum-deprivation (177,178). ERK 
activation at plasma membrane and inside of endosomes activates different downstream 
targets (179). Altered growth factor receptors trafficking processes are involved in 
tumorigenesis, like signaling from endosomes, recycling and dysregulation of 
degradation (180). It is also involved in therapy resistance, since lung cancer cells were 
resistant to gefitinib treatment by having impaired the trafficking of the phosphorylated 
receptor from early endosomes to late endosomes (181). Pro-survival autophagy 
mechanisms are also involved in surviving mechanisms to gefitinib (144,182,183). 
Further experiments, like immundetection of autophagosomes are required to test the role 
of autophagy in our model.  
But the role of endocytosis in gefitinib sensitivity is controversial in the scientific 
community. There is evidence that endocytosisimpairment increases gefitinib inhibition 
(145), but others showed the opposite, that endocytosis attenuates the signal (155). 
In our study, endocytosis impairment conferes total resistance to gefitinib. While gefitinib 
induces endocytosis probably to attenuate the EGFR signal. This attenuation should be 
evaluated by immunoblotting of the main downstream proteins of EGFR signaling 
pathway (AKT and ERK, total protein and phosphorylated one).  
But it remains to explain why U87 α5+ in the presence of gefitinib migrates more than 
the U87 α5-, while after endocytosis impairment both present the same phenotype. 
Importantly, in our different experiments we found that gefitinib activates β1 integrin 
endocytosis together with EGFR even in cells that express very low level of α5. This 
suggest that β1 is associated in other α subunit. It will be important in future to identify 
this α subunit and to understand why they are not able to trigger resistance to gefitinib. 
Integrin α5 can have a role in EGFR trafficking after endocytosis. Its role can be related 
to the recycling of EGFR back to the plasma membrane, where the signal can continue. 
There are already studies reporting the influence of integrin and EGFR recycling, and its 
role in promoting migration and invasion due to constitutive signaling activation 
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(131,184,185). But also integrin recycling (through endosomal and retrograde recycling) 
by itself is already described as an invasion promotor by reprogramming actin 
cytoskeleton and also by promoting the correct lamellipodia formation (151,186–189). 
EGFR recycling is involved in cellular migration in others physiological context, besides 
cancer as in keratinocytes and corneal epithelia (190,191). For that it should be interesting 
to study the receptors recycling in our model, or by using chemical inhibitors such as 
primaquine or using interference RNA against Rab 4 or 11(192,193). 
Even with still a lot of work ahead, this study allowed the highlight for endocytosis and 
trafficking importance in therapy resistance, in one of the most aggressive cancers 
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5. Conclusion 
 
Glioblastoma is an aggressive tumor without an effective therapy. Although EGFR is 
involved in glioma progression, targeted therapies failed in clinical trials. The cooperation 
between EGFR and integrin in the TK receptor trafficking is described as a potential 
therapy resistance mechanism. 
The main objective of this work was to determine if endocytosis has a role in gefitinib 
treatment, using for that dynamin inhibitors, impairing vesicle fission and consequently 
endocytosis. 
Using cell evasion assays, our team showed that U87 cells with higher levels of α5 
integrin are more resistant to gefitinib treatment. During my master, we showed that 
dynamin inhibition completely protects cells from gefinib activity in a α5 integrin 
independent way. Increase of EGFR endocytosis can be described as an important event 
in gefitinib treatment since EGFR is co-localized inside of early endosomes after 
treatment. This event is α5 independent even if α5 and β1 integrins are also 
internalized with gefitinib treatment in U87. Importantly we found that gefitinib induced 
EGFR and β1 endocytosis in several GBM cells lines. 
This work highlights endocytosis and trafficking importance in resistance to TKI 
targeting EGFR, in one of the most aggressive cancers. It remains to determine how α5β1 
can trigger resistance to gefitinib, likely during membrane trafficking downstream of 
endocytosis. 
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7. Annex 1- Antibodies list 
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